Document:

Exhibit 4.15

 

THE SYMBOL “****” DENOTES
PLACES WHERE PORTIONS OF THIS DOCUMENT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. SUCH MATERIAL WILL BE
FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

PRODUCT MANUFACTURING
AGREEMENT

 

This Product Manufacturing Agreement (“Agreement”)
is made as of the Effective Date by and between DEXCEL LTD., with its registered address at ****, Israel (“Dexcel”)
and KITOV Pharma Ltd., with its registered office at 132 Menachem Begin Road, Azrieli Center, Tel Aviv, 6701101, Israel
(“Kitov”). Dexcel and Kitov are hereinafter jointly the “Parties” and individually a “Party.”

 

		WHEREAS:	Dexcel is a pharmaceutical company engaged in various activities including, but not limited to,
the research, development, manufacture, and marketing of various drugs and pharmaceutical specialties in various dosage forms;

 

		WHEREAS:	Kitov is a pharmaceutical company engaged in various activities including, but not limited to,
the development of pharmaceutical products;

 

		WHEREAS:	Kitov and Dexcel entered into a Development Services Agreement on April 1, 2014 (“Development
Agreement”), pursuant to which Dexcel performed certain development services for Kitov with respect to the Product;

 

		WHEREAS:	Kitov desires that Dexcel manufacture and package the Product for Kitov in accordance with the
terms of this Agreement, and Dexcel is willing to manufacture and package the Product for Kitov in accordance with the terms of
this Agreement.

 

NOW, THEREFORE, in consideration
of the mutual covenants herein contained, the Parties, intending to be legally bound, hereby agree as follows:

 

		1	Definitions

 

For the purpose of this Agreement, the
terms set forth in this clause, whether used in singular or plural form, shall mean, unless otherwise expressly provided for in
this Agreement or the context otherwise requires, the following:

 

		1.1	“Affiliate” of a Party shall mean any corporation or other business entity directly
or indirectly Controlled by, under common Control with, or in the Control of such Party.

 

		1.2	“Anti-Corruption and Anti-Bribery Laws” shall mean the United States Foreign
Corrupt Practices Act of 1977, as amended, the Bribery Act 2010 (2010 Chapter 23) of the Parliament of the United Kingdom, any
rules or regulations under such acts, and any other anti-corruption or anti-bribery statutes, laws or regulations applicable to
a Party.

 

		1.3	“API” shall mean the active pharmaceutical ingredients Celecoxib and
Amlodipine Besylate.

 

     

     

    

 

		1.4	“Batch” shall mean the defined quantity of the Product processed in a single
process or series of processes in a manner designed to be homogeneous. The Batch size for the Product is **** tablets.

 

		1.5	“cGMPs” or “Good Manufacturing Practice” shall mean the part
of quality assurance which ensures that the Product is consistently produced and controlled to the quality standards appropriate
to their intended use, the principles and guidelines of which are specified in European Commission Directive 2003/94/EC and the
FDA’s current Good Manufacturing Practices, particularly 21 CFR § 210 et seq., and 21 CFR §§ 600-610, as both
may be amended from time to time.

 

		1.6	“Change of Control” shall mean (i) any change, sale, merger, reorganization,
or any other event or action that results in a third party, which is a material competitor to the other Party to this agreement,
acquiring: (a) all or substantially all of the business or assets of a Party relating to this Agreement, (b) Control, directly
or indirectly, of such Party (and/or any corporate entity that Controls, directly or indirectly, such Party), or (ii) any assignment
or delegation of, sale or transfer of a Party’s rights and obligations under this Agreement (or any part hereof) to a third
party.

 

Notwithstanding
anything in the immediately preceding paragraph to the contrary, where the Party in question is Dexcel, any of the foregoing events
or actions shall not be considered a Change of Control where any one or more of the relevant third party or parties referred to
in clause (i) above is (A) a Family Member, or (B) any entity Controlled by Mr. **** and/or a Family Member.

 

		1.7	“Claims” shall mean any demands, claims, actions, causes of action, assessments,
losses, damages, injuries, liabilities, costs and expenses (including, without limitation, reasonable attorneys’ fees and
expenses) filed, raised, initiated or made by any governmental authority and/or third party.

 

		1.8	“Confidential Information” shall have the meaning set forth in Section ‎7.1.

 

		1.9	“Confirmed Order” shall have the meaning set forth in Section 3.3.2.

 

		1.10	“Control” or “Controlled” shall mean possession of more than
fifty percent (50%) of the share capital of a corporation or other business entity, and/or the power to direct or cause the direction
of the management and policies of a corporation or other entity whether through the ownership of voting securities, by contract
or otherwise.

 

		1.11	“Delivery” shall mean the time when the Product is placed at the disposal of
Kitov at Dexcel’s Facility based on an ****  (Incoterms® 2010).

 

		1.12	“Distributors” shall mean any Person under contract with Kitov or any of its
Affiliates for the distribution of the Product in a certain territory or territories.

 

		1.13	“Effective Date” shall mean the date of signature of the last Party to execute
this Agreement.

 

		1.14	“EMA” means the European Medicines Agency or any successor entity.

 

		1.15	“Family Member” shall mean ****.

 

		1.16	“FDA” means the U.S. Food and Drug Administration or any successor entity.

 

    2

     

    

 

		1.17	“Force Majeure” shall mean an event beyond a Party’s reasonable control
which prevents such Party from performing its obligations hereunder, such events may include, but not be limited to, Acts of God
(including fire, flood, earthquake, storm, hurricane or other natural disaster), war, invasion, act of foreign enemies, hostilities
(regardless of whether war is declared), civil war, rebellion, revolution, insurrection, military or usurped power or confiscation,
terrorist activities, any extraordinary military operation which requires a large military reserve mobilization, nationalization,
governmental activities relating to emergency situations, blockage, embargo, strikes or lockouts.

 

		1.18	“Human Trafficking” shall mean the recruitment, transportation, transfer, harboring,
or receipt of men, women and/or children by improper means (such as force, abduction, fraud, or coercion) for an improper purpose
including forced labor or sexual exploitation.

 

		1.19	“Intellectual Property Rights” shall mean any inventions, information, results,
data, hypotheses, discoveries, developments, know-how, production methods, laboratory test results, owned or in the possession
of a Party, including, but not limited to, any patent, copyright, registered design, trademarks, trade secrets, or other industrial
or intellectual property right, including any and all improvements, enhancements, derivatives and residuals, whether registered
or unregistered and applications for any of the foregoing in any country, and any other intellectual property rights.

 

		1.20	“Joint IP” shall have the meaning set forth in Section 8.3 of the Development
Agreement as shown in Exhibit A

 

		1.21	“Kitov Data” shall mean, Kitov Foreground IP, including Patent families embodied
in Patents applications no. 13/026,741, 12/990,724, WO2009/154944 and WO2011/100659, and Kitov’s Confidential Information..

 

		1.22	“Kitov Foreground IP” shall have the meaning set forth in Section 8.1 of the
Development Agreement as shown in Exhibit A.

 

		1.23	“Kitov Product IP” shall have the meaning set forth in Section ‎2.1.1.

 

		1.24	“Label”, “Labeled” or “Labeling” shall
refer to: (i) all labels and other written, printed or graphic matter on the Product or any Packaging utilized with the Product,
or (ii) any written material accompanying the Product, including, without limitation, patient information leaflets (“PIL”).

 

		1.25	“Livery” or “Liveries” shall mean the graphics and text appearing
on each Pack of the Product, including the Trademark and any logos of Kitov and/or its Distributors, including, inter alia, the
requirements for serialization, as notified by Kitov to Dexcel in writing from time to time.

 

		1.26	“Marketing Authorization” shall mean an application to the appropriate Regulatory
Authority for approval to market the Product in any particular jurisdiction and all amendments and supplements thereto

 

		1.27	“Minimum Order Requirements” shall mean multiples of a full Batch.

 

		1.28	“Pack” shall mean a bottle containing either **** or **** tablets of the Product,
Labeled with the Livery.

 

		1.29	“Packaging” shall mean all primary containers (including bottles or blisters)
for the Product, plus cardboard cartons, PILs, shipping cases or any other like matter used in packaging and/or accompanying the
Product.

 

    3

     

    

 

		1.30	“Person” means any individual, entity or corporation of any kind, domiciled
in any jurisdiction.

 

		1.31	“Product” shall mean tablets containing the APIs Celecoxib/Amlodipine in three
dosage strengths (200/10mg, 200/5mg and 200/2.5mg), Labelled with the Livery and in Packs.

 

		1.32	“Quality Agreement” shall mean the agreement to be entered into by the Parties
pursuant to Section ‎4.1 below, which allocates the pharmaceutical
responsibilities and obligations of the Parties with respect to Product quality.

 

		1.33	“Quarter” shall mean the relevant three (3) month period ending on 31 March,
30 June, 30 September and 31 December in any calendar year, and any shorter period commencing on a day following the end of a Quarter
and ending on the expiration or termination of this Agreement.

 

		1.34	“Regulatory Authority” shall mean, in a particular country or jurisdiction,
any applicable governmental authority involved in granting a Marketing Authorization in such country or jurisdiction, including,
inter alia, the FDA and EMA.

 

		1.35	“Specifications” shall mean the pharmacochemical, manufacturing, stability and
other specifications of a Product defined in such Product’s Marketing Authorization, subject to change from time to time
as reasonably required to meet any requirements of the relevant Health Authorities.

 

		1.36	“Supply Commencement Date” shall mean the date upon which Dexcel makes the first
Delivery of the Product to Kitov pursuant to an Confirmed Order.

 

		1.37	“Supply Price” shall have the meaning set forth in Section ‎3.4.

 

		1.38	“Term” shall have the meaning set forth in Section ‎5.1.

 

		1.39	“Trademark” shall mean Kitov’s trademark ConsensiTM.

 

		1.40	“Working Day” shall mean a day excluding Friday and Saturday and, for the avoidance
of doubt, excluding statutory holidays in the State of Israel.

 

		1.41	“Year” shall mean the twelve (12) months following the Supply Commencement Date
and each successive twelve (12) month period commencing on the anniversary of the Supply Commencement Date.

 

		2	Basics of the Agreement

 

		2.1	Grant of Rights; Exclusivity

 

		2.1.1	Kitov hereby grants to Dexcel a fully paid, limited license right to use all of its Confidential
Information and Intellectual Property Rights (including, inter alia, the Kitov Foreground IP, Kitov Data, Kitov’s
share of the Joint IP, and the Trademark (“Kitov Product IP”)) necessary in order for Dexcel to manufacture,
Label, package with the Livery, test and release the Product for shipment, exclusively for Kitov, for and during the Term.

 

    4

     

    

 

		2.2	Kitov shall be responsible (itself or through its Affiliates and Distributors) for all costs related
to the maintenance of or changes to the Specifications, materials, suppliers of the API and/or other materials used for the manufacture
or Packaging of the Product, regulatory dossiers, and/or the Marketing Authorizations for the Product. Dexcel shall provide any
and all reasonable assistance to Kitov in this respect during the Term.

 

		3	Purchase and Supply of Product

 

		3.1	Packaging

 

		3.1.1	Kitov shall provide Dexcel with reasonable Packaging and Labelling instructions for the Livery
(by SKU), including, but not limited to, artwork for Labels and patient leaflets, as soon as practicable following the Effective
Date; provided, however, that Kitov shall provide such instructions at least one hundred and twenty (120) days prior to the anticipated
Supply Commencement Date. Kitov shall provide Dexcel with its Product Packaging and Labeling instructions, including, but not limited
to, approved artwork, with respect to any new SKU (for a new Product Distributor or new country), as well as changes to or destruction
of existing materials at least one hundred and fifty (150) days prior to the anticipated first supply of each such SKU.

 

		3.1.2	Kitov shall ensure that the Packaging and Labelling instructions and the Livery shall comply in
all respects with the relevant Marketing Authorizations.

 

		3.1.3	In the event that Kitov has Packaging requirements that are not standard for Dexcel, the Parties
shall discuss the implementation and costs of the same in good faith. Any additional costs and expenses incurred by Dexcel as a
result of such additional requirements shall be borne solely by Kitov.

 

		3.1.4	Dexcel shall order the Packaging materials required for the Product Packaging (including, but not
limited to, all Labeling); provided that such orders shall not exceed the forecasted demand of such materials for the next following
twelve (12) months. In the event that any Product artwork needs to be changed and/or discarded further to Kitov’s written
instructions or due to requirements of a relevant Regulatory Authority, Kitov shall fully bear any costs arising from any such
changes, including the costs of any discarded Packaging materials and/or any destruction costs. However, if such changes are required
to be carried out at Dexcel’s request, the cost for such changes shall be assumed by Dexcel.

 

		3.2	Kitov shall provide Dexcel with a twelve (12) month rolling forecast of its Product requirements
(by SKU), no later than the fifteenth (15th) Working Day of each Quarter (“Forecast”). The first Forecast will
be provided by Kitov to Dexcel at least six (6) months less one week prior to the anticipated Supply Commencement Date and shall
represent Kitov’s best estimates of the quantity of each Product SKU to be ordered during the twelve (12) months period covered
by the Forecast;.

 

		3.3	Purchase Orders

 

		3.3.1	Kitov shall provide Dexcel with written purchase orders meeting the Minimum Order Requirements
and in a form reasonably acceptable to Dexcel, and which shall specify at least the following: a description of the Product ordered,
the quantity ordered, the current Supply Price, and the required delivery date thereof, such required delivery date to be not less
than one hundred and twenty (120) days from the purchase order placement date (one hundred and eighty (180) days before the anticipated
Supply Commencement Date and/or the launch of a new SKU).

 

    5

     

    

 

		3.3.2	All Kitov purchase orders are subject to confirmation in writing by Dexcel, which confirmation
shall be delivered by e-mail within ten (10) Working Days of Dexcel’s receipt of each purchase order (each, a “Confirmed
Order”). If Kitov does not receive a response from Dexcel within such ten (10) Working Days, Kitov shall contact Dexcel
to confirm that Dexcel has received the purchase order. Except as provided in Section ‎3.3.3,
Dexcel shall use its best endeavors to accept all purchase orders placed by Kitov, which meet the Minimum Order Requirements and
the remaining terms and conditions of this Agreement.

 

		3.3.3	In the event that a Kitov purchase order is greater than Kitov’s Forecast by more than ****
percent (****%), Dexcel shall make a good faith determination of its ability to accept such purchase order, consistent with its
manufacturing schedule, the availability of the Product API and other materials, and its other planning requirements, in Dexcel’s
sole discretion.

 

		3.3.4	Dexcel will supply the Product only on the terms of this Agreement or any additional terms specifically
agreed upon in writing by both parties; in the event of any conflict, the provisions of this Agreement shall prevail.

 

		3.3.5	Dexcel shall use reasonable commercial efforts to deliver the Confirmed Orders to Kitov in full
on the required delivery date. Each shipment shall be accompanied by certificates of analysis and such other documents required
to be included pursuant to the Quality Agreement.

 

		3.3.6	Dexcel shall supply the Product with at least **** percent (****%) of the shelf life upon Delivery
unless otherwise agreed by the Parties.

 

		3.3.7	The Parties shall store and transport the Product in compliance with applicable laws and regulations
for pharmaceutical products, the Quality Agreement and the relevant Marketing Authorization. Dexcel will be responsible for packaging
the Product in a manner appropriate for shipment and for including data loggers with each such shipment in accordance with the
provisions of the Quality Agreement.

 

		3.3.8	Kitov shall be solely responsible, at its own cost and expense, for all activities related to the
sale, marketing, shipping, distribution, storage following the delivery of the Products, order fulfilment, invoicing, collection,
and any other activities directly or indirectly related to the promotion, marketing, distribution, or sale of the Product in any
country.

 

		3.4	The Supply Prices for the Product shall be:

 

	Strength	 	Pack Size	 	
        Supply
Price/Pack

(in US Dollars)
	200/10mg	 	Bottle **** tablets	 	****
	200/10mg	 	Bottle **** tablets	 	****
	200/5mg	 	Bottle **** tablets	 	****
	200/5mg	 	Bottle **** tablets	 	****
	200/2.5mg	 	Bottle **** tablets	 	****
	200/2.5mg	 	Bottle **** tablets	 	****

 

    6

     

    

 

		3.5	Supply Price modification

 

		3.5.1	Commencing with ****, Dexcel may adjust the Supply Price for the next following Year not more often
than ****.

 

		3.5.2	Dexcel shall deliver to Kitov, ****, a revised Supply Price to be effective for Product delivered
on or after the first day of the next Year; such revised Supply Price shall not be applicable to then-outstanding Confirmed Orders.

 

		3.6	Payment Terms

 

		3.6.1	All payments shall be made by bank transfer to such account as may be indicated by Dexcel, Dexcel
and Kitov each bearing their own bank transfer costs, net thirty (30) days from Delivery. All payments shall be made in U.S. Dollars.

 

		3.6.2	With the exception of amounts in legitimate dispute, in the event that Kitov is more than twenty
one (21) Working Days late in meeting the payment schedule set forth in Section ‎3.6.1,
Dexcel may, upon seven (7) Working Days’ written notice to Kitov (i) delay the delivery of Product ordered until the amounts
in arrears are paid, (ii) charge penalties on late payment with interest at the rate of **** per month from the due date for payment
until payment is actually made, and/or (iii) change or limit the terms of payment for future orders, including requiring the prepayment
for new orders or the provision of a letter of credit by Kitov (at Kitov’s expense) from a bank reasonably acceptable to
Dexcel.

 

		3.6.3	With the exception of amounts in legitimate dispute, in the event that Kitov fails to make any
payment due hereunder within ninety (90) days following the original due date, it shall be deemed a material breach of this Agreement
and shall entitle Dexcel, in its sole discretion, to terminate this Agreement with immediate effect.

 

		3.7	Product Acceptance

 

		3.7.1	The Product supplied by Dexcel to Kitov shall correspond to the respective Product Specifications
and the relevant Marketing Authorization and shall be manufactured in compliance with cGMP and the Quality Agreement.

 

		3.7.2	Kitov shall provide Dexcel with written notification of any shortfalls in shipment quantity, and
(a) any out-of-specification temperature excursions based on the downloaded data logger information following compliance with the
provisions of the Quality Agreement, and/or (b) any failure of the Product to meet the Specifications which are apparent upon visual
inspection and/or identification testing of the Product delivered to it by Dexcel (each of (a) and (b) being an “Apparent
Defect”), such notification to be provided within thirty (30) Working Days of receipt of the Product at Kitov’s
warehouse, accompanied by samples of any such allegedly defective Product and any such Product shall not be removed from quarantine
until their status is resolved. In the event that a defect is not apparent upon visual inspection during the shelf life of the
Product (“Hidden Defect”), Kitov shall use commercially reasonably best efforts to provide Dexcel with written
notification within thirty (30) Working Days of discovering the same, to be accompanied by samples of any such allegedly defective
Product, if such samples are available In the event of any failure by Kitov to provide Dexcel with written notification of any
such shortfall, Apparent Defect or Hidden Defect within the respective aforementioned periods, it shall be deemed as Kitov having
accepted the relevant consignment.

 

    7

     

    

 

		3.7.3	Dexcel shall use its best efforts to make up any shortfall in shipment quantity as soon as practicable
after being notified by Kitov of such shortfall. In the event of Product which Kitov claims have Apparent Defects or Hidden Defects,
Dexcel shall have up to thirty (30) Working Days after receipt of the samples to show that the Product in question meets the Specifications
(“Period”). In the event that no agreement is reached by the end of the Period, Kitov shall have the right to
submit a new purchase order, which Dexcel shall satisfy as soon as possible using reasonable commercial efforts (“Replacement
Shipment”), and Dexcel shall require proof that Kitov has destroyed that part or all of the original shipment with claimed
defective Product. In the event that Kitov has fully paid the Supply Price for the claimed defective Product, Dexcel shall supply
the Replacement Shipment at no additional Transfer Price. In the event that Kitov has not fully paid the Supply Price for the claimed
defective Product, Kitov will pay for the Replacement Shipment in accordance with the provisions of this Agreement (assuming the
Replacement Shipment meets the Specifications).

 

		3.7.4	Dexcel’s responsibility for Product supplied by it to Kitov failing to meet the Specifications
shall be limited to the replacement of the Product or the refund of the Supply Price paid by Kitov for such order, as agreed by
the parties, except as otherwise provided under this Agreement.

 

		3.7.5	In the event that the Parties do not agree on whether the Product meets the Specifications by the
end of the Period, the Parties agree to nominate an independent, reputable laboratory approved by the Regulatory Authority (“Laboratory”),
acceptable to both Parties, which shall examine representative samples taken from such consignment, using the methods of analysis
agreed upon by both Parties. The result shall be binding upon both Parties. Any charges for such examination shall be borne by
the Party found to be wrong in its assessment. In the event that Kitov receives a Replacement Shipment and the Laboratory decides
that the first shipment failed to meet the Specifications, Kitov shall only have to pay Dexcel for the Replacement Shipment. In
the event that Kitov receives a Replacement Shipment and the Laboratory decides that the first shipment met the Specifications,
Kitov shall have to pay for both shipments.

 

		4	Quality Agreement; Product Complaints and Recalls

 

		4.1	The Parties shall conclude the Quality Agreement as soon as practicable after the Effective Date,
but not later than ninety (90) days prior to the shipment of the initial order of the Product to Kitov.

 

		4.2	In case of a conflict between this agreement and the Quality Agreement, this agreement shall prevail
on any business matters, and the Quality Agreement shall prevail on any quality related matters.

 

    8

     

    

 

		4.3	Kitov shall have the right (at reasonable intervals, with reasonable prior written notice and during
normal business hours, and not more often than annually) to inspect Dexcel’s manufacturing facilities used in the manufacture,
storage, testing, and/or release for shipment of the Product.

 

		4.4	Kitov shall be responsible for the execution of Product recall and crisis management policies regarding
Product issues in the Territory. In the event of a Product recall in the Territory, Kitov shall promptly advise Dexcel and the
Parties shall reasonably cooperate with each other to take all necessary actions in that regard.

 

		4.5	Kitov shall be responsible for bearing the cost and expenses of any recall resulting from any of
the following: (i) damage to the Products which occurred after Delivery of the Products from Dexcel; (ii) any failure of the Livery
for the Product to comply with local laws or regulations in the relevant Territory; or (iii) any other action or non-action of
Kitov or a Distributor as promoter, marketer, distributor and seller of the Product in the Territory.

 

		4.6	Dexcel shall be responsible for bearing the cost and expenses of any recall resulting from: (i)
Dexcel’s acts or omissions as manufacturer of the Product, or (ii) the Product supplied by Dexcel not being in conformity
with the Specifications at Delivery.

 

		5	Term and Termination

 

		5.1	The Agreement shall commence on the Effective Date and remain in full force and effect for an initial
term of **** from the Supply Commencement Date of the Product (“Initial Term”). Following the Initial Term,
the Agreement shall automatically be renewed for additional periods of **** (each, a “Renewal Term,” and, together
with the Initial Term, the “Term”)), unless a Party provides written notification of non-renewal to the other
Party at least **** of the Initial Term or a Renewal Term.

 

		5.2	This Agreement may be terminated:

 

		5.2.1	by either Party, effective immediately upon written notice to the other Party, if (i) a receiver,
trustee, or liquidator of the other Party is appointed for any of properties or assets of the other Party; (ii) the other Party
makes a general assignment for the benefit of its creditors; (iii) the other Party files a petition under the relevant statute
for the bankruptcy or reorganization of the other Party or any arrangement with its creditors or readjustment of its debt, or its
dissolution or liquidation, or such a petition is filed against the other Party and is not dismissed within sixty (60) days thereafter;
or (iv) the other Party ceases doing business generally or commences dissolution or liquidation proceedings;

 

		5.2.2	in the event that a Party is in material breach of this Agreement or the Quality Agreement and
fails to remedy such breach within thirty (30) calendar days from receipt of written notification of same, by the non-breaching
Party;

 

		5.2.3	by Dexcel, in the event that the provisions of Section ‎3.6.3
is applicable; or

 

		5.3	in the event of a Change of Control, the Party which was not subject to the Change of Control may
terminate this Agreement upon six (6) months advance written notification. The affected Party is obligated to notify the other
Party of its decision to terminate within thirty (30) days following notice of the Change of Control.

 

    9

     

    

 

		5.4	Rights and Obligations Following Expiration or Termination

 

It is specifically understood
by Dexcel and Kitov that, upon any expiration or termination of this Agreement for any reason, the rights and obligations of the
Parties shall include the following:

 

		5.4.1	Neither Party shall be relieved of its duty to discharge in full all obligations accrued or due
prior to the date of termination, cancellation or expiration; all sums owed by either Party to the other shall become immediately
due and payable thirty (30) days after such date.

 

		5.4.2	Each Party shall remove all references to the other, if any, from its letterhead, business forms,
advertising literature, websites and place of business, and shall not thereafter use any name or trademark suggesting that it has
any current relationship with the other Party.

 

		5.4.3	Each Party shall return to the other all of the other’s Confidential Information and any
other material, information or samples relating to the Product which have been provided or made available to the other and shall
not retain any copies and the Parties further agree not to make any further use of each other’s Confidential Information
or any other information, data or samples relating to the Product provided or made available by the other Party, except as necessary
to comply with its statutory, regulatory or licensing obligations; provided, however, that Kitov may retain such material, information
and/or samples relating to the Product as may be necessary for Kitov to continue to sell the Product as permitted by Section ‎5.4.4
below, following which, Kitov shall refrain from making any further use of Dexcel’s Confidential Information or any other
information, data or samples and shall return any remaining Confidential Information and material, information or samples relating
to the Product.

 

		5.4.4	The provisions of this Section ‎5.4.4
shall not be applicable if Dexcel shall have terminated this Agreement pursuant to Sections ‎5.2.2
or ‎5.2.3. Any Confirmed Orders made by Dexcel on or
before the expiration or termination of this Agreement but not yet delivered by Dexcel shall be delivered to Kitov and Kitov shall
be liable to pay for the same in accordance with the provisions of the Agreement. Kitov shall be entitled to sell or otherwise
dispose of its remaining stock of the Product until the end of the inventory’s shelf life.

 

		5.4.5	In no event shall any expiration or termination of this Agreement excuse either Party from any
breach or violation of this Agreement and full legal and equitable remedies shall remain available therefor. The rights and obligations
of the Parties to this Agreement set forth in 4, 5, 6, 7, 9 and 10 shall survive any expiration or termination of this Agreement.

 

		6	Force Majeure

 

		6.1	If a Party asserts the occurrence of an event of Force Majeure as an excuse for its failure or
inability to perform such Party’s obligations, then the obligations of the Parties hereunder shall be suspended for so long
as the Force Majeure event renders performance of the Agreement impossible or impractical; provided, however, that (a) the nonperforming
Party shall timely notify the other Party in writing of the likelihood or actual occurrence of an event of Force Majeure by the
nonperforming Party; (b) the nonperforming Party must reasonably prove that it took all commercially reasonable steps to minimize
delay or damages caused by such event; and (c) the nonperforming Party substantially fulfilled all non-excused obligations, unless
the other Party has notified the nonperforming Party to the contrary.

 

    10

     

    

 

		6.2	In the event that such event of Force Majeure continues for a period in excess of sixty (60) days,
the Parties agree to undertake good faith discussions with a view to reaching some other mutually acceptable and reasonable arrangement
for alleviating the effects of such Force Majeure. In the event that the Parties are unable to agree on such an arrangement, either
Party shall be entitled to provide immediate written notice of termination to the other Party.

 

		7	Confidential Information

 

		7.1	For the purposes of this Agreement, “Confidential Information” shall mean, with
respect to a Party, all information of any kind whatsoever (including but not limited to, data, compilations, formulae, models,
patent disclosures, procedures, processes, projections, protocols, results of experimentation and testing, specifications, strategies
and techniques), and all tangible and intangible embodiments thereof of any kind whatsoever (including but not limited to apparatus;
compositions; documents; drawings; machinery; patent applications; records and reports), which is proprietary to the disclosing
Party or that is marked or identified by the disclosing Party or otherwise acknowledged by the recipient Party to be confidential
to the disclosing Party at the time of disclosure to the other Party.

 

		7.2	Confidential Information shall not include:

 

		7.2.1	Information that, at the time of disclosure by the disclosing Party, is in the public domain or
that, after disclosure, becomes part of the public domain except through a breach of this Agreement by the recipient Party; or

 

		7.2.2	Information that, at the time of disclosure by the disclosing Party, was known to the recipient
Party and was not acquired directly or indirectly from the disclosing Party and which the recipient Party can establish by competent
proof was in its possession at the time of disclosure; or

 

		7.2.3	Information that the recipient Party can establish by competent proof was lawfully received from
a third Party

 

		7.3	The Parties recognize that a Party within the framework of this Agreement may disclose Confidential
Information only in accordance with the terms of this Agreement (including this section 7)and that such disclosure represents confidential
and valuable proprietary information. Each Party promises and undertakes not to disclose the other Party’s Confidential Information
to any other person other than those of its and its Affiliates’ employees, directors, officers, consultants, and Distributors
(“Representatives”) who must have access to such information in order to utilize it for the purposes of this
Agreement. The recipient Party will take all reasonable steps to encourage and require its Representatives to preserve such trust
and confidence.

 

		7.4	The recipient Party shall accord the Confidential Information disclosed by the disclosing Party
with at least as careful treatment as the recipient Party accords to its own trade secrets, know how, and other proprietary information,
but no less than a reasonable level of care.

 

    11

     

    

 

		7.5	The recipient Party agrees not to use Confidential Information for any purpose other than within
the framework of the co-operation with the disclosing Party and to exercise its rights and carry out its obligations under this
Agreement. Upon any expiration or termination of this Agreement, at the disclosing Party’s request, the recipient Party agrees
to return to the disclosing Party all Confidential Information disclosed to the recipient Party by the disclosing Party.

 

		7.6	Nothing in this Agreement, nor any disclosure of Confidential Information by the disclosing Party
to the recipient Party before or after its execution, shall operate to confer any rights upon the recipient Party (other than the
rights set forth in this Agreement) nor be effective to license or transfer to the recipient Party any right, title or interest
in the Confidential Information, which rights shall remain the disclosing Party’s exclusive property.

 

		7.7	The Parties agree that neither Party may issue or release, directly or indirectly, any press release,
marketing material or other communications to third parties, the media or the public regarding the terms of this Agreement, the
other Party hereto, the Product, or the transactions contemplated hereby without the prior written approval of the other Party
hereto, such approval not to be unreasonably withheld, delayed or conditioned; provided, however, that nothing contained in this
Agreement shall prevent or preclude any Party from making such disclosures as may be required by applicable law, including, but
not limited to, any disclosures required by applicable securities laws.

 

		7.8	Required Disclosure. Notwithstanding the provisions of this Section 7, the recipient Party may
disclose the Confidential Information of the disclosing Party to the extent that such disclosure is reasonably necessary to:

 

		7.8.1	prosecute or defend litigation;

 

		7.8.2	comply with applicable governmental laws and regulations (including, without limitation, the applicable
laws, rules, regulations or requirements of a securities exchange or another similar regulatory body); or

 

		7.8.3	respond to a valid order, inquiry or request of, or make filings and submissions to, or correspond
or communicate with, any government authority.

 

In the event
that the recipient Party deems it reasonably necessary to disclose the Confidential Information of the disclosing Party pursuant
to this sub-Section 7.8, the recipient Party shall, to the extent possible, provide the disclosing Party with reasonable advance
notice of such disclosure to afford the disclosing Party a reasonable opportunity to take the necessary measures to prevent or
otherwise limit the disclosure, and in any event, the recipient Party shall limit the disclosure to the extent necessary to fulfill
the subject purpose described above and take reasonable measures to ensure confidential treatment of such information.

 

		8	Warranties, Indemnities and Insurance

 

		8.1	Kitov represents, warrants and covenants as follows:

 

		8.1.1	All necessary actions have been taken to enable it to execute and deliver this Agreement and perform
its obligations hereunder.

 

    12

     

    

 

		8.1.2	This Agreement is a valid and binding obligation of Kitov enforceable against it in accordance
with its terms. Kitov has the unencumbered right to enter into this Agreement and to fulfill its duties hereunder. It is not and
will not become Party to any agreement in conflict herewith.

 

		8.1.3	No approval, consent, order, authorization or license by, giving notice to or taking any other
action with respect to, any governmental or regulatory authority is required in connection with the execution and delivery of this
Agreement by Kitov and the performance by Kitov of its obligations hereunder.

 

		8.1.4	With respect to the Kitov Product IP, the Trademark and any remaining Kitov trademarks and logos,
Kitov warrants that, to the best of its knowledge, it has not interfered with, infringed upon, misappropriated, or otherwise come
into conflict with any valid intellectual property rights of any third party, nor has Kitov received, to the best of its knowledge,
any communications alleging any such interference, infringement, misappropriation, or violation (including any claim that Kitov
must license or refrain from using any intellectual property rights of any third party).

 

		8.1.5	The corporate policy of Dexcel is that all business be conducted within the letter and the spirit
of the law. Kitov warrants and represents that it will conduct the business contemplated hereunder in a manner which is consistent
with the Anti-Corruption and Anti-Bribery Laws, and it further warrants and represent that it will not:

 

		a)	Offer or give, either directly or indirectly, money or anything else of value to any person or
organization (including any government official) that is intended to, or could be seen as an attempt to, improperly influence or
reward such other person or organization in order to obtain or retain business or secure a business advantage for such person or
organization, Kitov (including its Affiliates, Distributors, agents, or other person associated with or acting on its or their
behalf) or Dexcel.

 

		b)	Request or accept, directly or indirectly, money or anything else of value if it is intended, or
could be seen as an attempt, to compromise Kitov’s independence or judgment, or to improperly influence a business decision
of Kitov or Dexcel.

 

		8.1.6	Kitov warrants that it has established and maintains a compliance program and reasonable internal
controls and procedures appropriate to ensure that Human Trafficking is not taking place in any part of its supply chain and in
any part of its own business, including, inter alia, the following:

 

		a)	Kitov and its Affiliates (and including any Distributors, agents, or other person associated with
or acting on their behalf) do not employ any person younger than the applicable legal minimum age for working, and children and
young people less than eighteen years of age are not employed in hazardous conditions.

 

		a)	Kitov and its Affiliates (and including any Distributors, agents, or other person associated with
or acting on their behalf) do not employ any person on an involuntary basis and do not use forced, prison, bonded, or indentured
labor.

 

    13

     

    

 

		b)	Kitov and its Affiliates (and including any Distributors, agents, or other person associated with
or acting on their behalf) fairly compensate their employees by paying wages and providing benefits that meet or exceed the applicable,
legally mandated minimum requirements in the countries in which they operate.

 

		8.2	Dexcel represents, warrants and covenants as follows:

 

		8.2.1	All necessary actions have been taken to enable it to execute and deliver this Agreement and perform
its obligations hereunder.

 

		8.2.2	Dexcel owns or has a valid license to all Dexcel IP rights relating to the Product. This Agreement
is a valid and binding obligation of Dexcel enforceable against it in accordance with its terms. Dexcel has the unencumbered right
to enter into this Agreement and to fulfill its duties hereunder. It is not and will not become Party to any agreement in conflict
herewith.

 

		8.2.3	No approval, consent, order, authorization or license by, giving notice to or taking any other
action with respect to, any governmental or regulatory authority is required in connection with the execution and delivery of this
Agreement by Dexcel and the performance by Dexcel of its obligations hereunder.

 

		8.2.4	Dexcel warrants and represents that it will conduct the business contemplated hereunder in a manner
which is consistent with the Anti-Corruption and Anti-Bribery Laws, and it further warrants and represent that it will not:

 

		a)	Offer or give, either directly or indirectly, money or anything else of value to any person or
organization (including any government official) that is intended to, or could be seen as an attempt to, improperly influence or
reward such other person or organization in order to obtain or retain business or secure a business advantage for such person or
organization, Kitov or Dexcel.

 

		b)	Request or accept, directly or indirectly, money or anything else of value if it is intended, or
could be seen as an attempt, to compromise Dexcel’s independence or judgment, or to improperly influence a business decision
of Kitov or Dexcel.

 

		8.2.5	Dexcel warrants and represents that it has established and maintains a compliance program and reasonable
internal controls and procedures appropriate to ensure that Human Trafficking is not taking place in any part of its supply chain
and in any part of its own business.

 

		8.2.6	Dexcel warrants that its facilities for manufacturing the Product are cGMP-approved and that it
will manufacture the Product in accordance with this Agreement, cGMPs, the Marketing Authorization and the Specifications.

 

		8.3	Any breach of warranty, representation or covenant hereunder shall constitute a breach of contract.

 

    14

     

    

 

		8.4	EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, DEXCEL MAKES NO WARRANTY, EXPRESSED OR IMPLIED,
AND SPECIFICALLY MAKES NO WARRANTY OF MERCHANTABILITY OR WARRANTY OF FITNESS FOR ANY PARTICULAR PURPOSE, REGARDING THE PRODUCTS
OR ANY OTHER MATTER WITH RESPECT TO THE TRANSACTIONS CONTEMPLATED HEREBY.

 

		8.5	Indemnification

 

		8.5.1	Dexcel agrees to defend, indemnify and hold Kitov and its Affiliates, and their respective officers,
directors, and employees (collectively, the “Kitov Indemnitees”) harmless from and against any Claims arising
from (i) any product liability claims related solely to Dexcel’s actions as the manufacture of the Product, or (ii) any breach
by Dexcel or its Affiliates of its representations, warranties, covenants, agreements or obligations under this Agreement, in all
cases except to the extent such damages give rise to an indemnification claim by Dexcel under Section ‎8.5.2
below.

 

		8.5.2	Kitov agrees to defend, indemnify and hold Dexcel and its Affiliates, and their respective shareholders,
officers, directors, and employees (collectively, the “Dexcel Indemnitees”) harmless from and against any Claims
arising from (i) the handling, possession, use, marketing, distribution, promotion or sale of any Product by Kitov or its Affiliates
or any of their Distributors, employees or subcontractors or agents following Delivery of the Product to Kitov, (ii) any breach
by Kitov or its Affiliates of its representations, warranties, covenants, agreements or obligations under this Agreement, (iii)
any intellectual property infringement claims with respect to the Product or the Trademark; or (iv) any product liability claims,
whether arising out of warranty, negligence, strict liability (including manufacturing, design, warning or instruction claims)
or any other product or quality based claims in relation to the Product, in all cases except to the extent such damages give rise
to an indemnification claim by Kitov under Section ‎‎8.5.1
above.

 

		8.5.3	Unless and to the extent otherwise specifically provided herein, in the event that the Dexcel Indemnitees
or the Kitov Indemnitees intend to claim indemnification under this Section ‎8.5
with respect to any third party claim or action (such one of the Dexcel Indemnitees or the Kitov Indemnitees being herein referred
to as the “Indemnitee”) shall promptly notify the other Party (the “Indemnitor”) of any loss,
claim, damage, or liability arising out of any third party claim or action in respect of which the Indemnitee intends to claim
such indemnification, and the Indemnitor shall assume the defense thereof with counsel of its own choosing. Additionally, an Indemnitee
shall have the right to retain its own counsel with the reasonable fees and expenses to be paid by the Indemnitor, however only
in the event the representation of such Indemnitee by the counsel retained by the Indemnitor would be inappropriate due to an actual
conflict of interest between such Indemnitee and any other Party represented by the Indemnitor’s counsel in such proceedings.

 

		a)	An Indemnitee shall not be entitled to indemnification under this Section ‎8.5
if any settlement or compromise of a third party claim is concluded by the Indemnitee without the prior written consent of the
Indemnitor, which consent shall not be unreasonably withheld, delayed or conditioned.

 

		b)	An Indemnitor shall not enter into any settlement or compromise of any third party claim or consent
to the entry of any judgment or other order with respect to any claim: (i) which does not contain, as a part thereof, an unconditional
release of the Indemnitee for liability for all loss, cost or damage that may arise from such claim; or (ii) which contains any
injunctive or other non-monetary relief that might in any way interfere with the future conduct of business by the Indemnitee,
unless, in either case, the Indemnitee otherwise consents thereto in writing.

 

    15

     

    

 

		c)	Any Indemnitee, and its employees, agents and representatives, shall cooperate fully with the Indemnitor
and its legal representatives, at the Indemnitor’s sole expense for out-of-pocket costs, in the investigation of any action,
claim or liability covered by this indemnification provision.

 

		8.6	Each Party shall maintain (a) comprehensive general liability insurance (including without limitation,
coverage for bodily injury, personal injury, property damage, casualty loss and contractual and trademark liability); and (b) product
liability insurance, providing full indemnification and defense against claims, liabilities, damages, demands and causes of action,
alleged or actual, arising out of any defects in or use of the Product under this Agreement (including manufacturing, design, warning,
or instruction claims), in such amounts as it customarily maintains for similar products and activities, but in no event less than
$5,000,000 per individual claim and $10,000,000 in the aggregate. At the time of entering this Agreement, each Party shall be fully
insured and shall duly maintain such insurance during the term of this Agreement and thereafter for so long as it customarily maintains
insurance for itself for similar products and activities. Each Party shall provide the other Party with proof of such insurance
upon request. Each Party shall cause such insurance policies to provide that the other Party shall be given at least thirty (30)
days’ notice of any cancellation, termination or change in such insurance.

 

		8.7	Without prejudice to any other limitation (whether effective or not) of either Party’s liability,
neither Party shall be liable to the other Party (whether in contract, tort (including negligence) or for breach of statutory duty
or otherwise) for any loss of profits, use, opportunity, goodwill, business or anticipated savings, for any indirect, incidental,
special, indirect, punitive or consequential losses (in each case, irrespective of any negligence or other act, default or omission
of a Party (or its employees or agents) and regardless of whether such loss or claim was foreseeable or not and whether the other
Party has been informed of the possibility of such loss). Nothing in this Section ‎8.7
shall operate to limit or exclude any liability under Section ‎8.5
with respect to a Claim, or for fraud, or for breach by a Party of the provisions of Article ‎7.

 

		9	Intellectual Property Rights

 

		9.1	It is agreed that the Parties shall keep each other informed, on a complete and timely basis, about
any claim, demand, award, or damages, whether direct or consequential, that is asserted or assessed based upon any allegation,
suit or judgment that the Kitov Product IP infringes any patent or other intellectual property right of a third party (an “IP
Claim”) and about any action resulting therefrom. The Parties shall exchange, free of charge, any documentation received
from the third party filing the IP Claim, and shall also send each other copies of the documents issued by any of them, regarding
such IP Claim.

 

		9.2	In the event that any third party files, in or out of court, any IP Claim against Kitov or Dexcel,
alleging infringement of intellectual property rights as a consequence of or derived from the performance of any of the operations
contemplated in this Agreement, Kitov shall, in its reasonable judgment, decide the defense strategy, the means of proof, the choice
of counsel, and the appeals. Neither Party shall settle and/or negotiate, or start conversations to seek a settlement or a negotiation,
either in or out of court, any IP Claim without having obtained the prior written approval of the other Party. Both Parties shall
collaborate on the necessary exchange of documentation and information available in order to be able for each Party to take action
with respect to an IP Claim.

 

    16

     

    

 

		9.3	All of the Kitov Product IP, including the Marketing Authorizations (but excluding any of Dexcel’s
Intellectual Property Rights), shall be retained by Kitov at all times, and Dexcel shall have no rights with respect to the Kitov
Product IP, except for any rights provided to it pursuant to the terms of this Agreement and the Development Agreement.

 

		10	Governing Law; Venue

 

		10.1	This Agreement shall be interpreted and enforced exclusively under the laws of the State of Israel,
without regard to the conflict of laws provisions thereof.

 

		10.2	The Parties submit to the exclusive jurisdiction of the competent courts of Tel-Aviv in any dispute
related to this Agreement without giving effect to choice of law rules. Notwithstanding the aforesaid, the Parties shall endeavour
in good faith to settle amicably any dispute which may arise between them under or in connection to this Agreement.

 

		11	Miscellaneous

 

		11.1	The provisions of this Agreement shall be binding upon and inure to the benefit of the Parties
hereto and their respective successors and assigns. Notwithstanding the aforesaid, either Party shall be entitled to assign, delegate,
and/or subcontract its rights and obligation under this Agreement, in whole or in part, to one or more of its Affiliates on prior
written notice to the other Party. For purposes of this Agreement, any merger, consolidation, or change of corporate structure
following which there is a Change of Control of Kitov shall be considered as an assignment by Kitov, allowing Dexcel to terminate
the Agreement as heretofore provided.

 

		11.2	This Agreement (including all attachments hereto and the Quality Agreement), sets forth the entire
agreement between the Parties relating to the subject matter contained herein and may not be modified, amended or discharged except
as expressly stated in this Agreement or by a written agreement signed by the Parties hereto, except that this Agreement shall
not supersede or serve to amend (i) any separate confidentiality or non-disclosure agreement that may have been entered into by
the Parties, or (ii) the Development Agreement, each of which shall remain in effect in accordance with its terms.

 

		11.3	The provisions of this Agreement shall be deemed separate. Therefore, if any part of this Agreement
is rendered void, invalid or unenforceable, such rendering shall not affect the validity and enforceability of the remainder of
this Agreement unless the part or parts which are void, invalid or unenforceable shall substantially impair the value of the whole
Agreement to either Party.

 

		11.4	Unless otherwise stated in this Agreement, any and all communications required as provided for
in this Agreement shall be in writing to the addresses noted above and shall be sent by (i) Certified or Registered Mail, postage
prepaid, return receipt requested, (ii) confirmed email or facsimile followed by a letter of confirmation sent by any of the methods
stated in (i) and/or (iii) of this clause, or (iii) by an express overnight courier service (for example, Federal Express or Airborne),
postage prepaid, return receipt requested and addressed as set forth above. Notices shall be deemed given three (3) days following
mailing by Certified or Registered Mail, and one (1) day following overnight courier. Either Party may give written notice of a
change of address. After such notice has been received, any notice thereafter shall be given to such Party as above provided at
such changed address.

 

    17

     

    

 

		11.5	The headings used in this Agreement are for the convenience of the Parties only, and shall not
be considered in interpreting or applying the provisions of this Agreement.

 

		11.6	Nothing in this Agreement shall be deemed or construed to constitute between the Parties the relationship
of principal and agent, or employer and employee, nor to create any partnership, joint venture or other form of legal association
of any nature whatsoever. Neither Party is hereby constituted a legal representative of the other Party for any purpose whatsoever
and neither is granted any right or authority hereunder to assume or create, whether in writing or otherwise, any obligation or
responsibility, express or implied, or to make any representation, warranty or guarantee, or otherwise to act in any manner in
the name of the other Party.

 

		11.7	This Agreement may be executed in any number of counterparts, each of which shall be deemed an
original and all of which taken together shall be one and the same agreement. Signatures to this Agreement transmitted by facsimile,
by electronic mail in “portable document format” (“.pdf”), or by any other electronic means which
preserves the original graphic and pictorial appearance of the Agreement, shall have the same effect as physical delivery of the
paper document bearing the original signature.

 

IN WITNESS WHEREOF, the Parties have caused
their authorized officials to execute this Agreement as of the date first set forth above.

 

	Dexcel Ltd.	 	Kitov Pharma Ltd. 
	 	 	 	 	 
	By:	 	 	By:	 
	Name:  	 	 	Name:  	 
	Title:	 	 	Title:	 
	Date:	 	 	Date:  	 
	 	 	 	 	 
	 	 	 	By:	 
	 	 	 	Name:  	 
	 	 	 	Title:  	 
	 	 	 	Date:  	 

 

    18

     

    

 

Exhibit A

 

		8.1.	Any Intellectual
                                         Property Rights or Confidential Information belonging to either Kitov or Dexcel prior
                                         to the execution of this Agreement will remain the sole property of either Kitov or Dexcel,
                                         respectively (“Kitov Foreground IP” and “Dexcel Foreground
                                         IP”, respectively).

 

		8.2.	Kitov hereby grants to Dexcel a fully paid, limited, non
exclusive, license to use Kitov Data in as much as required for the provision of the Services by Dexcel.

 

		8.3.	Subject
                                         to the provisions of sections 8.1 and 8.2 above and without derogating therefrom, any
                                         and all rights, title and interest in any Intellectual Property Rights resulting from
                                         any development made by Dexcel which is related to the Product and embodied in the Deliverables
                                         or conceived in connection with the services provided hereunder by Dexcel to Kitov, which
                                         is only applicable for the manufacture, research, development, making of, use, sale,
                                         production, commercialisation and distribution of the Product, shall be jointly and equally
                                         (50%/50%) owned by Dexcel and Kitov (the “Joint. IP”).

 

 

19Exhibit 4.16

 

THE
SYMBOL “****” DENOTES PLACES WHERE PORTIONS OF THIS DOCUMENT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT. SUCH MATERIAL WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

EXECUTION
COPY

 

AGREEMENT

 

THIS AGREEMENT
(collectively with all exhibits hereto, the “Agreement”) is made and entered into as of December 27, 2018 (the
“Effective Date”), by and between Kitov Pharma Ltd., a company existing under the laws of the State of
Israel with a principal place of business at One Azrieli Center, Round Tower, Floor 19, Tel Aviv, Israel (“Kitov”),
and Coeptis Pharmaceuticals, Inc., a Pennsylvania corporation with a principal place of business at 105 Bradford Road, Suite
420, Wexford, PA 15090 (“Coeptis”).

 

WHEREAS,
Kitov controls rights to the CONSENSITM product as further described in Exhibit A hereto (the
“Product”); and

 

WHEREAS,
Coeptis has the knowledge, skill and experience to sell and distribute products such as the Product within the Territory, as defined
in Section 1.3.); and

 

WHEREAS,
Kitov and Coeptis desire that Coeptis distribute the Product on an exclusive basis within the Territory on the terms and subject
to the conditions set forth in this Agreement.

 

NOW,
THEREFORE, the Parties, intending to be legally bound, hereby agree as follows:

 

		1.	Appointment and Rights.

 

		1.1.	Appointment. Subject to the terms and conditions of this Agreement, Kitov hereby grants
to Coeptis, for the Term, as defined in Section 13.1), an exclusive, right to market, distribute and sell the Product solely to
Customers located in the Territory. As used herein, the term “Customer” shall refer to licensed pharmaceutical
distributors including but not limited to wholesalers, pharmacies, hospitals and medical centers, as well a third parties for research
and development purposes.

 

		1.2.	NDA Transfer Kitov hereby grants to Coeptis all
rights and regulatory responsibilities to NDA N210045 - Consensi (Amlodipine Besylate; Celecoxib) (the “NDA”) for
the Term of this Agreement.

 

		1.3.	Reservation of Rights; Restrictions. Except for the rights granted to Coeptis herein, Kitov
reserves all rights in and to the Product. Coeptis will not, directly or indirectly, use, copy, market, distribute, or otherwise
transfer or make available the Product or any ancillary materials or documents provided to Coeptis by Kitov related thereto to
any entity for any purpose or in any manner other than as expressly permitted in this Agreement.

 

		1.4.	Territory. Coeptis may market and distribute the Product solely in the United States and
Puerto Rico (the “Territory”). The scope of the Territory may be modified only with the written agreement of
the Parties. Coeptis will not knowingly solicit orders from any prospective purchaser whose principal place of business is located
outside the Territory. Coeptis will not seek customers for the Product outside the Territory or otherwise engage in activities
which it knows or would reasonably be expected to lead to sales of the Product outside the Territory. If Coeptis receives any order
for Products from a prospective purchaser located outside the Territory intending to distribute or dispense such Products outside
the Territory, Coeptis will promptly refer that order to Kitov, and Coeptis will not accept such orders without Kitov’s prior
written consent. Where known to Coeptis, Coeptis will notify Kitov in writing about any attempt by individuals or entities within
the Territory to distribute the Product outside the Territory.

 

     

     

    

 

		1.5.	Non-Compete. Coeptis shall not distribute or manufacture any Competing Products during the
Term, unless Coeptis presented these Competing Products to Kitov and received Kitov’s prior written consent to such manufacturing
or distribution, at Kitov’s sole and absolute discretion, (the “Non-Compete”). For purposes hereof, the
term “Competing Product” means a combined drug comprised of an NSAID and an anti-hypertensive agent.

 

		2.	Orders Fulfillment, Pricing and Consideration.

 

		2.1.	Orders and Delivery. Coeptis shall order Products
solely from Kitov or a manufacturer approved in the NDA, and such manufacturer shall be responsible for manufacturing and supplying
Products to Coeptis. Coeptis will be required to enter into a Supply Agreement and Quality Agreement with Kitov or such other
manufacturer, as applicable. Kitov will be required to support Coeptis with orders and delivery, as requested by Coeptis. Coeptis
will have the right to contract manufacturing with an alternative supplier upon written consent from Kitov, which consent shall
not be unreasonably conditioned, delayed or withheld. In the event Coeptis utilizes an alternative supplier, Coeptis shall seek
approval for Kitov to have the ability to also purchase Products from such alternative supplier in order to fulfill commitments
by Kitov with respect to the Product in other areas outside the Territory.

 

		2.2.	CMC and Post Marketing Commitments Kitov and Coeptis
will operate in accordance with the Chemistry, Manufacturing, Contol (“CMC”) Plan, including but not limited
to engineering and scale-up batches, validation, stability, and post-marketing commitments, which is attached hereto as Exhibit
B.

 

		2.3.	Consideration. In consideration for the rights granted
hereunder, Coeptis shall pay Kitov the following:

 

		2.3.1.	Fee. A cash fee of US $3.5 million (inclusive of
the CMC Reimbursement Payment) to be paid by Coeptis to Kitov as follows (each payment below shall be referred to herein, without
derogating from any specific definition of a particular payment, a “Milestone Payment”):

 

		2.3.1.1.	Upon the execution of the Agreement, Coeptis will pay Kitov
a non-refundable, non-creditable upfront fee of $1,000,000 (One million United States Dollars) in cash; and

 

		2.3.1.2.	Upon Completion of the CMC Plan as set forth in Exhibit
B, Coeptis will reimburse Kitov for CMC costs incurred by Kitov up to an amount of US $**** (**** United States Dollars) (“CMC
Reimbursement Payment”) in cash; and

 

		2.3.1.3.	Upon first commercial sale of Product in the Territory
by or on behalf of Coeptis (“FCS”), Coeptis will pay Kitov a non-refundable, non-creditable milestone payment
of $**** (**** United States Dollars) in cash.

 

		2.3.1.4.	Payment Terms.
                                         The foregoing Milestone Payments shall be made as soon as possible upon achievement
                                         of the applicable milestone, but no later than within 45 days of the achievement of the
                                         applicable milestone; provided, however, that the payment in Section 2.3.1.1 shall be
                                         made simultaneously with execution of the Agreement (a “Milestone Payment Deadline”).

 

		2.3.2.	Profit Distributions. Following FCS, Coeptis will
pay Kitov an “Initial Profit Distribution” equal to 60% of Net Profits of the Product, until Kitov has received
Initial Profit Distributions of $13,000,000 (thirteen million United States Dollars) (the “Initial Profit Distribution
Threshold”). Once this Initial Profit Distribution Threshold has been achieved, Coeptis will pay Kitov “Continuing
Profit Distributions” equal to 40% of the Net Profits through the term of the Agreement. As used herein, “Profit
Distribution(s)” shall mean Initial Profit Distributions and/or Continuing Profit Distributions, in aggregate and/or
individually, as applicable.

 

    2

     

    

 

		2.3.3.	Coeptis Profits/Revenue Participation. Following the earlier of a) FCS by Coeptis or b) cumulative expenditures by Coeptis of $3,000,000 (inclusive
of Milestone Payments made under Section 2.3.1) in the product in accordance with this agreement, in the event that any party other
than Coeptis acquires rights with respect to the Product (including to commercialize) in the Unites States, (i) if the party is
Kitov, Kitov will pay to Coeptis an ongoing quarterly distribution equal to 10% of the net profits realized by Kitov in respect
of the commercialization of the Product and (ii) if the party is not Kitov, Kitov will pay to Coeptis, within 5 days of receipt
of same, 10% of any and all revenues received by Kitov from any third party (whether such revenues are derived under license agreements,
co-promotion agreements or otherwise). The profits/revenues participation provided for in this Section 2.3.3 shall survive the
expiration or termination of this agreement.

 

		2.3.4.	As used herein, “Net Profits” shall
mean (A) with respect to time periods during which Initial Profit Distributions are made, Net Sales less the following; (i) Cost
of Goods, including CMC costs, including CMC Reimbursement Payment (ii) A Sales and Marketing Allowance equal to ****% of Net
Sales, (iii) Intellectual Property Costs, and (iv) Regulatory Filing and Marketing Authorization Costs (including for the avoidance
of doubt all fees paid to the FDA or any other regulatory body) in connection with the Product in the Territory actually incurred
during each such time period and (B) with respect to time periods during which Continuing Profit Distributions are made, Net Sales
less the following; (i) Cost of Goods, including CMC costs, including CMC Reimbursement Payment (ii) A Sales and Marketing Allowance
equal to ****% of Net Sales, (iii) Intellectual Property Costs, and (iv) Regulatory Filing and Marketing Authorization Costs (including
for the avoidance of doubt all fees paid to the FDA or any other regulatory body) in connection with the Product in the Territory
actually incurred during each such time period;

 

		2.3.5.	As used herein “Cost of Goods” shall mean, with respect to a certain time period,
the purchase price (including freight and insurance costs) of the Products sold incurred by Coeptis, based on the average cost
inventory method

 

		2.3.6.	As used herein, “Net Sales” shall mean, with respect to a certain time period,
the gross amount billed or invoiced by or on behalf of Coeptis and/or its Affiliates and/or any sublicensee of the above (the “Invoicing
Entity”) with respect to sales of Products and/or with respect to, inter alia, license royalties, milestone payments
or other similar payments (“Gross Sales”) (whether made before or after the FCS), less the following: (a) customary
trade, quantity, or prompt pay discounts to the extent actually allowed and taken, including government rebates; (b) amounts repaid
or credited by reason of rejection or return, that the Invoicing Entity has not and will not dispute; (c) to the extent separately
stated on purchase orders, invoices, or other documents of sale, any taxes or other governmental charges levied on the production,
sale, transportation, import, export, delivery, or use of a Product which is paid by or on behalf of the Invoicing Entity; and
(d) outbound transportation, packing and delivery charges, as well as prepaid freight (including shipping insurance) actually incurred;
provided, however, that, (i) in any transfers of Products between the Invoicing Entity and an Affiliate of the Invoicing Entity
not for the purpose of resale by such Affiliate, Net Sales shall be equal to the fair market value of the Products so transferred,
assuming an arm’s length transaction made in the ordinary course of business; and (ii) in the event that the Invoicing Entity,
or the Affiliate of the Invoicing Entity, receives non-monetary consideration for any Products or in the case of transactions not
at arm’s length with a non-Affiliate of the Invoicing Entity, Net Sales shall be calculated based on the fair market value
of such consideration or transaction, assuming an arm’s length transaction made in the ordinary course of business. Sales
of Products by an Invoicing Party to an Affiliate of such Invoicing Party, for resale by such Affiliate, shall not be deemed Net
Sales and Net Sales shall be determined based on the total amount invoiced or billed by such Affiliate on resale to an independent
third party Customer.

 

    3

     

    

 

		2.3.7.	Until such time as Kitov has fully-engaged a new manufacturer for the product, all CMC costs (whether
or not contemplated by the CMC Plan) will be paid for by Kitov, and reimbursed by Coeptis in accordance with Section 2.3.1.2. From
and after such time as Kitov has fully engaged a new manufacturer, Coeptis will pay all CMC costs. Any CMC costs reimbursed by
Coeptis, or incurred by Coeptis, will be accounted for through the calculation of Net Profits.

 

		2.3.8.	As used herein, “Intellectual Property Costs” shall mean all expenses actually
incurred in the prosecution and maintenance of patents and other intellectual property in the Territory.

 

		2.4.	Payment Terms. The foregoing Profit Distribution payments shall be made contemporaneously
with Coeptis’s submission of the Report (as defined in Section 3.4 below), that is within 60 days of the completion of each
calendar quarter. No part of any amount payable to Kitov hereunder may be reduced due to any counterclaim, set-off, adjustment,
withholding or other right which Coeptis may have against Kitov, unless otherwise agreed between the parties as part of good faith
discussions.

 

		2.5.	Taxes. All payments under Section 2.3 shall be subject to any required withholding, if any.
Each party will pay any and all taxes levied on account of any payments made to it under this Agreement.

 

		3.	Marketing, Reporting and Compliance.

 

		3.1.	Marketing and Promotion. Coeptis will use its reasonable commercial efforts to actively
market, promote and sell Products within the Territory, including but not limited to the utilization of contracted sales organizations,
co-promotion partners, marketing agencies, and other third party promotional parties, in accordance with the applicable Marketing
Plan (as defined below). Without limiting the generality of the foregoing, the Parties, as applicable, agree to the following terms:

 

		3.1.1.	Within 90 days from the Effective Date, Coeptis shall prepare
and deliver to Kitov a detailed prelaunch plan for the Products (the “Pre-Launch Marketing Plan”) substantially
consistent with the plan in Exhibit D. Not less than 60 days prior to the end of each calendar year during the Term of
this Agreement, Coeptis shall prepare and deliver to Kitov an updated multi-year sales and marketing plan for the Products (the
“Annual Marketing Plans”, and together with the Pre-Launch Marketing Plan the “Marketing Plans”).
The Pre-Launch Marketing Plan and the Annual Marketing Plans shall contain specific objectives, targets and forecasts for sales
during the calendar year, Product pricing and the marketing and/or promotional and/or reimbursement qualification activities Coeptis
intends to undertake (including specific details, to the extent known, regarding Coeptis’s participation in exhibitions
and conferences, patient advocacy programs, arrangements with Key Opinion Leaders, as well as specific details regarding Coeptis’s
intended applications to insuring bodies for reimbursement coverage. The Annual Marketing Plans will stipulate a budget to be
dedicated solely to marketing and/or promotional and/or reimbursement qualification activities; and

 

		3.1.2.	The Annual Marketing Plans will include a target number of sales force representatives for the
marketing and sale of the Product in the Territory. Coeptis shall ensure that such representatives shall be appropriately trained,
and shall obtain their undertaking to perform their responsibilities in a professional manner and in compliance with all applicable
laws and regulations. Coeptis shall be solely responsible for such representatives’ engagement terms, including for compensating
and insuring such representatives, and for any and all applicable mandatory payments and remittances.

 

		3.1.3.	Coeptis shall have the sole right to determine and set
Product prices in the Territory, which shall all be in accordance with the Pre-Launch Marketing Plan and the Annual Marketing
Plans.

 

		3.2.	Records and Audit Rights. Coeptis will keep accurate records with respect to its activities
pursuant to this Agreement including, without limitation, with respect to Products sold and to whom Products are sold. Coeptis
will make such records available to an independent auditor appointed by Kitov during regular business hours upon pre-coordination.
Kitov shall bear the costs of such audit; provided, however, that if such audit reveals any material lack of compliance
with the terms of this Agreement or applicable laws and regulations, or that Coeptis has underpaid any Profit Distribution due
pursuant to the terms of this Agreement by more than ten percent (10%) of the amount properly due and owing to Kitov, then Coeptis
shall bear all costs of the audit and (regardless of the magnitude of the underpayment) shall promptly, and in any case within
ten calendar days, pay Kitov all unpaid Profit Distributions. Any audit conducted pursuant to this Section 3.2 shall be conducted
in a manner reasonably acceptable to Coeptis so as to minimize the disruption to Coeptis’s day-to-day operations, and Kitov’s
auditors shall be subject to a non-disclosure agreement customary for engagements of this type.

 

    4

     

    

 

		3.3.	Reimbursements. Coeptis shall be solely and entirely responsible for all pricing reimbursement
and market access activities in the Territory. Coeptis expressly undertakes to apply for reimbursement qualification and applicable
codes with respect to the Product with all major insurers and/or HMOs in the Territory, and actively take all necessary steps to
ensure that the Product is qualified for reimbursement.

 

		3.4.	Reports. Within 30 days following the end of each calendar quarter following FCS, Coeptis
will provide Kitov with a written report, (a “Report”) which will include, at a minimum, the following information
regarding the immediately preceding quarter: (i) quantities of all Products sold during such calendar quarter and at what price(s),
(iii) total Gross Sales (iv) total Net Sales; (v) the detail of costs by which Gross Sales was reduced to arrive at Net Sales;
(vi) the amount of Profit Distribution due to Kitov; and (vii) updates, if any, on implementation of the Marketing Plan. Additionally,
Coeptis shall promptly provide Kitov with details regarding each report received by it of any serious and adverse incident involving
the use of the Product. Such report shall be made as soon as required under applicable laws and regulations and in no case later
than five calendar days after receiving written notice of the incident. Coeptis shall also provide Kitov with any information known
to Coeptis relating to the competitive environment for the Products and laws and regulations applicable to the sale or use of its
Products in the Territory.

 

		3.5.	Regulatory Compliance. From and after thirty (30) days after the Effective Date, Coeptis
shall assume all obligations of, and be, the holder of the marketing authorization for the Product and will assume responsibility
for all regulatory and pharmacovigilance activities and compliance in the Territory, under relevant laws and regulations in the
Territory, including, but not limited to those applicable regulations administered by the U.S. Food and Drug Administration, for
so long as Coeptis is the distributor of the Product in the Territory. For the avoidance of doubt, Coeptis shall, report adverse
events, file relevant reports, and perform all activities required under relevant laws and regulations in the Territory of the
holder of the approved New Drug Application for the Product. Coeptis will bear the cost of all regulatory fees, such as, inter
alia, any FDA assessed user fees for the Products, and which allow for the marketing the Product during the term the Agreement,
in each case from and after the Effective Date. For so long as Coeptis is responsible for all regulatory and pharmacovigilance
activities and compliance in the Territory, Coeptis shall (i) provide Kitov with full and regular access to all documents and information
related to such activities and compliance, and (ii) notify Kitov promptly of any changes to the applicable laws and regulations
of which it is aware that may impact the distribution, marketing, sales and use of the Product in the Territory. As of the Effective
Date Coeptis shall serve as Kitov’s local US address for the Product and FDA purposes, it being clarified that all communication
and correspondence in connection therewith shall be coordinated with Kitov and shall be consistent with the other terms of this
Agreement.

 

		3.6.	SDEA. The Parties shall enter into a Safety Data Exchange Agreement (SDEA) describing the
procedures which Kitov and Coeptis shall implement, and the responsibilities of each Party thereunder
to ensure that relevant safety information relating to the Product is exchanged in a timely manner and that Parties can fulfill
their respective pharmacovigilance obligations under applicable laws

 

		3.7.	Compliance. Coeptis shall be responsible for complying with all laws, standards and regulations
in the Territory applicable to the importation, marketing, demonstration, distribution and sales of the Product, including, without
limitation, obtaining any necessary import, insurance, and other certifications, licenses and permits. Kitov or its designated
manufacturer is responsible for complying with all laws, standards and regulations governing the manufacture and exportation of
the Products. Each Party shall be solely responsible, at its sole cost and expense, for compliance with all laws and regulations
governing the conduct of its business in all jurisdictions in which it conducts business. Each Party will at all times conduct
its business in a way that will reflect favorably on the other Party and the Product and will not knowingly partake in any illegal
or questionable business practices.

 

    5

     

    

 

		4.	Proprietary Rights; Kitov Marks.

 

		4.1.	Proprietary Rights. Except for the rights explicitly granted under this Agreement (which
include, for the avoidance of doubt, the exclusive license from Kitov to Coeptis to use same in the Territory), (i) title to and
ownership of all proprietary rights (including, without limitation, patent, copyright, trade secret and trademark rights) in or
related to the Product and related documentation including, without limitation, all regulatory filings, remains at all times with
Kitov, and (ii) neither Party is granting to the other Party any rights in or to any intellectual property owned or controlled
by it.

 

		4.2.	Kitov Marks. Coeptis will market the Product to
Customers only under the name selected by Kitov or other Kitov-owned marks approved in writing by Kitov, and not under any other
brand name. Coeptis will neither remove nor conceal any trademark, trade name or logo appearing on Products or related documentation
nor add any other marking to the same without Kitov’s prior written consent in each instance. To the extent that Coeptis
is expressly permitted hereunder to make copies of related documentation or any part thereof pursuant to the terms of this Agreement,
Coeptis agrees to reproduce and include such notices, markings and insignias on all such copies.

 

		4.3.	Use of Marks. Subject to the terms hereof, Kitov
hereby grants Coeptis a limited, nontransferable and royalty-free license to use Kitov’s trade names, trademarks, logos
and service marks listed in Exhibit C, as may be amended from time to time by Kitov in accordance with the terms hereof
by written notice to Coeptis (hereinafter referred to as the “Marks”) and associated goodwill only during the
Term (as defined below) and solely for display, advertising and other marketing and promotional purposes in connection with selling
and distributing Products in accordance with this Agreement in the Territory. Coeptis shall not register any Marks or derivatives
thereof without first giving Kitov the opportunity to register same for itself (in which case any such newly registered Mark shall
be automatically included in the license under this Agreement), and Coeptis will follow all reasonable written instructions from
Kitov with respect to use of the Marks. Kitov reserves the right to add to the use of the Marks, on a selective or general basis,
at any time, by providing written notice to Coeptis. For the avoidance of doubt, any use of Kitov materials or the Kitov name
on the internet, other than in the normal course of business, shall be subject to the prior written approval of Kitov, and Coeptis
acknowledges and agrees that all right, title and interest in and to the foregoing shall vest exclusively in Kitov. Coeptis agrees
that Kitov may register Coeptis as an authorized user of the Marks and shall cooperate with Kitov in such respect upon request.
Kitov covenants and agrees that (i) all trade names, trademarks, logos and service marks under which the Products may be marketed
and sold shall be included on Exhibit C, and (ii) all Products sold to Coeptis shall be delivered in packaging consistent with
the Marks and as otherwise reasonably acceptable to Coeptis.

 

		4.4.	Goodwill, etc. All goodwill arising from Coeptis’ use of Marks will inure to the benefit
of Kitov. Upon the expiration or termination of this Agreement for any reason, the limited license of the Marks granted hereunder
shall immediately terminate and Coeptis shall cease all use of the Marks. Title to and ownership of all proprietary rights in or
related to the Marks remains at all times with Kitov. Coeptis further irrevocably assigns and will assign to Kitov in perpetuity
all worldwide right, title and interest, if any, that are owned or obtained by Coeptis during the Term in any of the Marks.

 

		4.5.	Audit. Without derogating from the general applicability of Section 3.2, Kitov shall also
have the right to periodically review Coeptis’s compliance with the provisions of this Section 4. Such review shall be coordinated
in advance with Coeptis and will be conducted during Coeptis’s normal business hours in a manner reasonably acceptable to
Coeptis so as to minimize the disruption to Coeptis’s day-to-day operations. Coeptis shall cooperate with Kitov with respect
to any such review, including by way of making relevant information available to Kitov, and shall work in good faith with Kitov
to resolve any non-compliance with this Section 4 as identified by Kitov in connection with its review.

 

    6

     

    

 

		5.	Joint Steering Committee.

 

Joint
Steering Committee. Commencing with the Effective Date, the Parties shall establish a joint steering committee (the “Joint
Steering Committee” or “JSC”) to oversee the implementation of the Marketing Plan, including pricing,
reimbursement and market access of the Product and all commercial strategies undertaken by Coeptis with respect to the Product.
The JSC shall have access to all data related to the marketing, sale and distribution of Products in the Territory. Each Party
shall be entitled to designate two representatives to the Joint Steering Committee (the “Representatives”).
The Parties shall ensure that their respective Representatives shall be bound by the confidentiality arrangements set out in this
Agreement. The first meeting of the JSC shall be held as soon as practicable, but no later than 30 days after the Effective Date
and thereafter the Joint Steering Committee shall meet at least once per quarter. Meetings shall be at locations and times to be
mutually agreed upon by the Parties. The JSC may make decisions with respect to any subject matter that is subject to the JSC’s
decision making authority and responsibilities as set forth above, unless provided otherwise in this Agreement. Regardless of the
number of individuals attending any JSC meeting, each Party shall have a single vote.

 

The
Representatives shall attempt to reach consensus prior to making any material decisions; provided, however, that where -
after good faith efforts - such consensus is not achieved, then the Chief Executive Officers from Kitov and Coeptis shall be entitled
to make the final decision through mutual agreement, which decision shall be binding upon the Parties. All activities conducted
by and decisions made by the JSC shall be consistent with and subject to the provisions of this Agreement, and the JSC shall not
have any power to take any action that conflicts with the terms of this Agreement or to amend, modify or waive compliance with
any of the terms of this Agreement. Coeptis shall provide the JSC copies of all reports required to be delivered by it to any party
under this Agreement. Both Parties shall provide the JSC with regular updates regarding any regulatory activity in which it is
involved related to the Product. All information disclosed by Representatives in the course of their participation on the JSC shall
constitute Confidential Information hereunder.

 

		6.	Confidentiality.

 

		6.1.	Each Party (the “Receiving Party”) agrees to keep confidential during and after
the termination of this Agreement and not to disclose to any third party, and not to use except in performance of its obligations
and exercise of its rights under this Agreement, confidential or proprietary information related to the other Party’s technology
or business that it receives from the other Party (the “Disclosing Party”) or learns in connection with this
Agreement, regardless of the medium in which it was provided. The term “Confidential Information” means any
information designated orally or in writing as confidential or which, in light of the nature of the information or the circumstances
of disclosure, should reasonably have been construed as being confidential and will include (but will not be limited to) the following
information (a) technology, trade secrets, inventions, ideas, processes, formulas, source and object codes, data, programs, other
works of authorship, know-how, improvements, discoveries, developments, designs and techniques; and (b) information regarding plans
for research, development, new products, manufacturing, marketing and selling, business plans, budgets and unpublished financial
statements, licenses, prices and costs, suppliers, customers and any data and information relating to the Product that is not for
distribution to Customers. Confidential Information will not include information (i) already lawfully known by the Receiving
Party prior to its disclosure by the Disclosing Party as evidenced by contemporaneous written documentation, (ii) independently
developed by the Receiving Party without access to or use of the Disclosing Party’s Confidential Information as evidenced
by written documentation, (iii) which is at the time of disclosure or later becomes publicly known under circumstances involving
no breach of this Agreement by the Receiving Party, or (iv) lawfully obtained from any third party who is not under an obligation
of confidentiality to the Disclosing Party. The Receiving Party will not, directly or indirectly, alter, reverse engineer, decompile,
disassemble or otherwise modify the Confidential Information. For clarity, any Confidential Information regarding the Product will
be the Confidential Information of Kitov. Without limiting the foregoing, the Receiving Party may disclose Confidential Information
to officers, directors, employees, representatives, professional advisors and prospective acquirers of all or substantially all
of the Receiving Party’s business, provided in each case that the Party to whom such disclosures are made are bound by written
obligations of confidentiality at least as restrictive as those set forth in this Agreement.

 

    7

     

    

 

		6.2.	Except as is necessary to comply with applicable laws and regulations or the rules of any exchange
on which a Party’s securities are traded, each Party will keep the terms of this Agreement confidential. Neither of the Parties
nor any of their respective Affiliates shall issue any press release or public announcement concerning this Agreement or the transaction
contemplated hereby without obtaining the prior written approval of the other Party hereto unless (i) required by law or applicable
exchange listing requirements or (ii) in connection with a potential transaction involving the sale of all or substantially all
of the assets of a Party or the sale by a Party of a control equity position (so long as the counterparty to the proposed transaction
has signed a confidentiality agreement that fully covers the Confidential Information to at least the same extent covered in this
Agreement). Any Party so required by law or applicable exchange listing requirements to make a public or other disclosure shall
make reasonable commercial efforts in order to coordinate such disclosure with the other Party and/or to obtain confidential treatment
for the matters concerning this Agreement or the transaction contemplated hereby or any other Confidential Information, such that
any legally required disclosure by one Party shall be restricted so as not to include the identifying details nor any commercially
sensitive information of the other Party, and the Party so required to make such disclosure will furnish only that portion of the
Confidential Information which such Party is advised by written opinion of its legal counsel is legally required, and shall exercise
all commercially reasonable efforts to obtain assurances that confidential treatment will be accorded such disclosure to the greatest
extent possible.

 

		6.3.	Notwithstanding anything to the contrary in this Agreement, in case any Confidential Information
is information that may be considered “material non-public information” pursuant to the securities laws and regulations
governing a Party and the securities exchanges on which its shares are traded - the other Party hereby undertakes not to make any
unlawful use of such Confidential Information, including by way of effecting a transaction in a security of the other Party while
the Confidential Information or any part thereof is in such Party’s possession. Each Party represents that it is aware and
will advise its shareholders, directors, officers, employees, consultants and agents who are informed of any of the matters that
are the subject of this Agreement, of the restrictions imposed by applicable securities laws on the purchase or sale of securities
by any person who has received material, non-public information regarding a company with publicly traded securities, as well as
the restrictions making it unlawful to communicate such information to any other person when it is reasonably foreseeable that
such other person is likely to purchase or sell securities in reliance upon such information. Furthermore, any filings of this
Agreement or of other confidential treatment requests shall be coordinated in good faith between the Parties.

 

		6.4.	Each Party acknowledges that any violation or threatened violation of the confidentiality terms
of this Agreement may cause irreparable injury to the other Party, entitling the other Party to seek equitable relief, including
injunctive relief and specific performance, in addition to all other legal remedies to which such Party may be entitled in any
court of competent jurisdiction.

 

		6.5.	No public announcement or other disclosure to Third Parties concerning the existence of or terms
or provisions of this Agreement shall be made, either directly or indirectly, by any Party to this Agreement, except as may be
legally required, including, without limitation, as required by any regulatory agency or applicable stock exchange rules or requirements,
or as may be required for recording purposes, without first obtaining the written approval of the other Party and agreement upon
the nature and text of such announcement or disclosure. The Party desiring to make any such public announcement or other disclosure
shall inform the other Party of the proposed announcement or disclosure in reasonably sufficient time prior to such public release
and shall provide the other Party with a written copy thereof in order to allow such other Party to review, comment upon and approve
the announcement or other disclosure, which such approval shall not be unreasonably withheld or delayed. A Party shall not be required
to seek the permission of the other Party to report any information as to the existence and terms of this Agreement that has already
been publicly disclosed, or is required to be publicly disclosed, by such Party in accordance with the foregoing or by the other
Party, however, the Parties shall consult with each other in issuing any press releases or other public announcements with respect
to this Agreement or of the transactions contemplated hereby. Either Party may disclose the terms of this Agreement to such Party’s
directors and professional advisors and to potential investors, acquirers or merger partners and their professional advisors who
are in each case bound by written or professional obligations of non-disclosure and non-use that are at least as stringent as those
contained in this Section 6 or are customary for such purpose.

 

    8

     

    

 

		7.	Intellectual Property.

 

		7.1.	Definitions

 

		7.1.1.	“Control” means, with respect to any Patent, Know-How or other intellectual
property right, that the Party (or its Affiliate) controlling such right owns a transferable interest or has a license to utilize
such Patent, Know-How or right and has the ability to grant the other Party access, a license or a sublicense (as applicable) to
utilize such Patent, Know-How or right without violating the rights of any Third Party.

 

		7.1.2.	“Improvement” means any and all technical information, whether patentable or
non-patentable, and whether owned, owned jointly or Controlled by either Party or its Affiliates which covers any improvement,
invention or discovery concerning the Product including, without limitation, new or improved methods of manufacture, formulas,
uses, indications, methods of delivery and dosage forms thereof.

 

		7.1.3.	“Know-How” means all present and future technical information specifically relating
to the Product, including all biological, toxicological, chemical and biochemical information, metabolic, non-clinical, pre-clinical,
clinical, pharmacological and pharmacokinetic data, as well as Product- related information in respect of physico-chemical properties,
assays, formulations, quality control, synthetic processes, and manufacturing methods and data, specifications, and any other information
relating thereto.

 

		7.1.4.	“Kitov Patents” means all Patents that
relate to the Product in the Territory Controlled by Kitov or its Affiliates and licensees and sublicensees as of the Effective
Date, and all Patents that relate to the Product or Improvements thereof in the Territory that become Controlled by Kitov or its
Affiliates, which are listed on Exhibit C, as amended and updated from time to time.

 

		7.1.5.	“Patent” means all patents and patent applications, including provisional and
priority filings, and which specifically or generically claim the Product, claim a use for the Product, claim a method of making
the Product or otherwise covers the Product, including but not limited to the patent applications listed on Exhibit C, together
in all cases with any continuations, continuations-in-part, divisions, patents of addition, reexaminations, reissues, renewals
as well as extensions and supplementary protection certificates of any of the foregoing.

 

		7.2.	Ownership and Disclosure. All intellectual property, including any Patents or Know-How,
developed by Kitov related to the Product shall be owned by Kitov. All intellectual property including any Patents or Know-How
developed by Coeptis related to the Product shall be owned by Coeptis, which shall provide Kitov with a license for such intellectual
property for its use in jurisdictions other than the Territory.1

 

		7.3.	Prosecution and Maintenance.

 

		7.3.1.	Kitov shall have full responsibility for prosecution and
maintenance, of the Kitov Patents worldwide. Kitov shall provide Coeptis with a reasonable review period and allow for Coeptis
comment on any patent application as well as any patent prosecution of Kitov Patents to be filed by Kitov in the Territory. Coeptis
will make recommendations for the patent application and prosecution in the Territory, and Kitov will duly consider all suggestions
and recommendations made by Coeptis, in Kitov’s reasonable discretion; provided however, that any prosecution decision by
Kitov that would have a material adverse effect on the protection of the Product in the Territory will require Coeptis’s
prior written consent, not to be unreasonably withheld, conditioned or delayed. In the event that Kitov elects not to prosecute
or maintain any Kitov Patent in the Territory, Kitov shall provide thirty (30) day notice of that election, and Coeptis shall
have the right, at its sole discretion, to assume responsibility, including financial responsibility, for prosecution and maintenance
of any such Kitov Patents in the Territory.

 

    9

     

    

 

		7.3.2.	Kitov will use reasonable efforts to promptly file patent
applications in the Territory for patentable improvements made by Kitov. Kitov will share with Coeptis all such patent prosecution
materials related to the Territory and will use reasonable efforts to allow for Coeptis to comment thereon. Coeptis will make
recommendations for the patent application and prosecution in the Territory, and Kitov will duly consider all suggestions and
recommendations made by Coeptis. With regard to the geographic scope of any patent application, Kitov will inform Coeptis whether
Kitov’s proposed list of intended countries for filing includes the Territory. Should Coeptis desire applications to be
filed in the Territory, Kitov will use reasonable efforts to file in the Territory, at Coeptis’ expense.

 

		7.4.	Validity Challenge. In the event that a Third Party challenges the validity of any particular
Kitov Patents in the Territory, including by pre-grant opposition, post-grant opposition or revocation proceeding, Kitov will use
reasonable efforts to allow Coeptis to provide input and comment on the conduct of the defense of such claim, and Coeptis shall
give all reasonable assistance to Kitov in connection with such defense. Kitov has the right to control the suit and proceeding
with respect to such defense of the Kitov Patents. In the event that Kitov assumes control and defense of a claim in the Territory,
Kitov shall not agree to any settlement of the suit without the prior written consent of Coeptis, such consent not to be unreasonably
withheld, conditioned or delayed. In the event that Kitov elects not to assume control or defense of such a suit or claim with
respect to the Kitov Patents in the Territory, then Coeptis, at its discretion, may assume control or defense of such claim, at
Coeptis’ cost. In the event that Coeptis assumes control or defense of any action, Kitov shall give all reasonable assistance
to Coeptis, at Coeptis’s cost. Coeptis shall not agree to any settlement of the suit without the prior written consent of
Kitov, not to be unreasonably withheld or delayed.

 

		7.5.	Patent Term Extension. Coeptis shall cooperate with Kitov in obtaining any extension of
the term of the Kitov Patents or any other similar period of exclusivity, which may be available under the laws and regulations
in the Territory.

 

		7.6.	Notification of Infringement. If either Party learns of any misappropriation or unauthorized
disclosure of Kitov Know-How, or any infringement or threatened infringement by a Third Party of any Kitov Patents, in each case
in the Territory, then, such Party will promptly notify the other Party and will provide such other Party with all available evidence
of such misappropriation or infringement.

 

		7.7.	Infringement Proceedings. The Parties’ rights and obligations with respect to any
Third-Party misappropriation or infringement in the Territory shall be as follows:

 

		7.7.1.	If Coeptis shall have supplied Kitov with written evidence
demonstrating to Kitov’s reasonable satisfaction prima facie infringement of a claim of a Kitov Patent or any misappropriation
or unauthorized disclosure of Kitov Know-How in the Territory by a Third Party which poses a material threat to Coeptis’s
rights under this Agreement, Coeptis will have the right, but not the obligation, to institute, prosecute and control at its own
expense and in its own name, any action or proceeding with respect to such infringement, misappropriation or unauthorized disclosure
by counsel of its own choice, and will consult with Kitov on any actions that Coeptis proposes to take in such action or proceeding.
Kitov will cooperate with Coeptis in any such action or proceeding brought by Coeptis against a Third Party, all at Coeptis’s
cost, and Kitov will have the right to consult with Coeptis and to participate in and be represented by independent counsel of
its own choice in such litigation at its own expense; provided however, that Coeptis and its counsel shall remain in control of
such litigation and make all significant decisions relating to the prosecution of such action.

 

    10

     

    

 

		7.7.2.	If Coeptis fails to bring an action or proceeding or otherwise
take appropriate action in Coeptis’s discretion to abate such infringement, misappropriation or unauthorized disclosure
in the Territory within a period of ninety (90) days of written notice by Kitov to Coeptis requesting such action, Kitov will
have the right, but not the obligation, to bring and control, by counsel of its own choice, at its own expense, any such infringement,
misappropriation or unauthorized disclosure action or proceeding. Coeptis will cooperate with Kitov in any such action or proceeding
brought by Kitov against a Third Party, and will have the right to consult with Kitov and to participate in and be represented
by independent counsel of its own choice in such litigation at its own expense; provided however, that Kitov and its counsel
shall remain in control of such litigation and make all significant decisions relating to the prosecution of such action.

 

		7.7.3.	If one Party brings any such action or proceeding under
this Section 7, the other Party agrees, at the request and expense of the first Party, to be joined as a party plaintiff to the
extent necessary to prosecute the action or proceeding and to give the first Party reasonable assistance and authority to file
and prosecute the suit. Any amounts recovered by either Party pursuant to this Section 7 will first be used to reimburse the Parties
for any out-of-pocket litigation expenses (including reasonable attorney’s fees and expenses) and any other legal expenses
incurred pursuant to such enforcement. If either Party brings an action under this Section 7, then any remaining amounts recovered
by such Party following such reimbursement as aforesaid will be deemed Net Profits subject to the applicable Profit Distribution
as calculated in this Agreement.

 

		7.7.4.	Settlement with a Third Party. The Party that controls
the prosecution of a given action under Section 7 will also have the right to control settlement of an action described above;
provided, however, that no settlement will be entered into with respect to a Patent without the written consent of the party owning
such Patent, if such settlement would require the party to be subject to an injunction or make a monetary payment in excess of
US$10,000 or would restrict the claims in or invalidate any of the Patents.

 

		7.8.	Patent Marking. Coeptis and its Affiliates and any subcontractors thereof shall cause all
Product shipped to or sold in the Territory to be marked in such a manner as to conform with the patent laws and practices of the
Territory, as well as applicable regulations.

 

		8.	Relationship of the Parties.

 

		8.1.	Independent Contractor. The Parties are independent contractors. In no event shall the Parties’
relationship established hereunder be construed to be that of employer and employee, or to constitute a joint venture or agency
of any kind. In no event will Coeptis’s employees or agents be considered employees of Kitov or be entitled to any benefits
that Kitov may provide to its employees.

 

		8.2.	No Power to Bind. Kitov has no right to enter into, and covenants and agrees that it shall
not enter into or hold itself out as having the authority to enter into, any contracts or commitments in the name of, or on behalf
of, Coeptis, or to bind Coeptis in any respect whatsoever. Coeptis has no right to enter into, and covenants and agrees that it
shall not enter into or hold itself out as having the authority to enter into, any contracts or commitments in the name of, or
on behalf of, Kitov, or to bind Kitov in any respect whatsoever. In marketing and other dealings relating directly or indirectly
to the Product, Coeptis will clearly indicate that it is acting as a licensee of, and not as the owner or developer of, the Product.

 

		8.3.	[intentionally omitted]

 

		8.4.	Expenses. Except as expressly set forth herein, each Party will be solely and fully responsible
for any expenses that it incurs in the negotiation of this Agreement and the performance of its obligations hereunder.

 

		9.	Representations and Warranties.

 

		9.1.	Each Party represents and warrants to the other Party that: (i) the execution, delivery and performance
of this Agreement will not result in the breach or violation of any law or regulation applicable to it or any contract or commitment
by which it is bound; (ii) it has obtained every permit, authorization, license or consent from any person or entity (including
any governmental authorities) required to perform its obligations and exercise its rights under this Agreement; and (iii) this
Agreement has been duly authorized by all necessary corporate action, and upon execution and delivery of this Agreement by both
Parties, this Agreement shall constitute a binding agreement of the Party enforceable against such Party in accordance with its
terms. Each Party further represents, warrants and undertakes that it is conducting and shall conduct its businesses in compliance
with all applicable Corrupt Practices Laws, and its internal management and accounting practices and controls are adequate to ensure
compliance with Corrupt Practices Laws applicable to such Party. As used herein, Corrupt Practices Laws” means any
law, regulation, order, decree, or directive having the force of law and relating to bribery, kick-backs, or similar business practices
in effect from time to time.

 

		9.2.	Coeptis further represents, warrants and undertakes that Coeptis shall (i) on a date by no later
than **** following the date of execution of this Agreement, Coeptis will have secured the necessary financial resources to fulfill
its obligations under Section 2.3.1.2 and 2.3.1.3 of this Agreement, including the necessary steps to achieve a FCS within ****
following the date of execution of this Agreement;; and (ii) use commercially reasonable efforts to market and sell the Products
within the Territory and to obtain and maintain all regulatory and other approvals and permits necessary to undertake its obligations
pursuant to this Agreement including, without limitation, with respect to the marketing and distribution of the Products.

 

    11

     

    

 

		9.3.	Kitov further represents and warrants that Kitov shall
use ongoing, commercially reasonable efforts to obtain and maintain all regulatory and other approvals and permits necessary to
obtain marketing approval for, and to otherwise market and distribute, the Product in all governing jurisdictions within the Territory.

 

		9.4.	Kitov further represents and warrants that (i) the Products
and Marks do not infringe upon or misappropriate the intellectual property rights of any third party, and (ii) provided that Coeptis’s
activities in relation to the aforementioned activities are in accordance with the terms of this Agreement, Coeptis’s promotion,
marketing, distribution, offer for sale, sale, use, importation and other transfer or disposal of Products in the Territory does
not and will not infringe upon or misappropriate the intellectual property rights of any third party. Kitov further represents
that it has not, prior to the Effective date, received any notice of or allegation of an infringement upon or misappropriation
of the intellectual property rights of any third party.

 

		10.	Limited Warranty. EXCEPT AS EXPRESSLY STATED
IN THIS AGREEMENT, KITOV MAKES NO WARRANTY, WHETHER EXPRESS OR IMPLIED, WRITTEN OR ORAL (INCLUDING ANY WARRANTY OF MERCHANTABILITY
OR FITNESS FOR A PARTICULAR PURPOSE), WITH RESPECT TO THE PRODUCT OR OTHERWISE, ALL OF WHICH ARE EXPRESSLY EXCLUDED TO THE FULLEST
EXTENT PERMITTED BY APPLICABLE LAW.

 

		11.	Limitation of Liability. TO THE FULLEST EXTENT
PERMITTED BY APPLICABLE LAW, AND EXCEPT IN THE CASE OF A PARTY’S INDEMNIFICATION AND NONDISCLOSURE OBLIGATIONS HEREUNDER,
OR ITS INTENTIONAL MISCONDUCT OR FRAUD, THE AGGREGATE LIABILITY ARISING OUT OF THIS AGREEMENT FOR EITHER PARTY WHETHER BASED UPON
WARRANTY, CONTRACT, TORT OR OTHERWISE, WILL BE LIMITED TO THE AGGREGATE AMOUNT PAID TO KITOV BY COEPTIS HEREUNDER DURING THE 12
MONTH PERIOD IMMEDIATELY PRECEDING THE CLAIM OR LEGAL ACTION CREATING THE LIABILITY. TO THE FULLEST EXTENT PERMITTED BY APPLICABLE
LAW, AND EXCEPT IN THE CASE OF A PARTY’S INDEMNIFICATION AND NON-DISCLOSURE OBLIGATIONS HEREUNDER, AS WELL AS ITS INTENTIONAL
MISCONDUCT OR FRAUD, IN NO EVENT WILL EITHER PARTY BE LIABLE FOR SPECIAL, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES OR LOSSES,
INCLUDING, BUT NOT LIMITED TO, ANY LOST PROFITS OR OPPORTUNITIES, ARISING OUT OF, RELATING TO, OR IN CONNECTION WITH THIS AGREEMENT,
INCLUDING THE MANUFACTURE, SALE OR SUPPLY OF THE PRODUCTS, EVEN IF SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES
OR LOSSES. THE FOREGOING LIMITATIONS SHALL NOT APPLY IN THE CASE OF GROSS NEGLIGENCE OR WILLFUL MISCONDUCT BY SUCH PARTY.

 

		12.	Indemnification and Insurance.

 

		12.1.	Indemnity by Coeptis. Coeptis will defend and/or
indemnify Kitov, its Affiliates and all of their officers, directors and employees, from and against any and all claims, damages,
costs, expenses, judgments, and monetary awards, penalties, or fines, actually incurred based upon, arising out of or relating
to (a) Coeptis’ s negligence or willful breach of any covenant contained herein; (b) any material breach of any of Coeptis’
s representations obligations under this Agreement; or (c) Coeptis’s failure to take any required action pursuant to Section
3. 5and to the extent such action is not a result of Kitov’s gross negligence or willful misconduct ;provided, however,
that: (i) Kitov will have promptly provided Coeptis with written notice thereof and reasonable cooperation, information, and assistance
in connection therewith, at Coeptis’s cost; and (ii) where, in the reasonable assessment of Kitov’ s counsel, no conflict
of interest exists, Coeptis will have control and authority with respect to the defense, settlement, or compromise thereof; provided
that with respect to (ii) above, in the event that Kitov undertakes such control and authority, it shall do so at its own
cost and expense; and provided further that no such settlement or compromise will be binding unless approved in writing
in advance by the non-controlling Party, and Kitov will have the sole right to control any claim relating to the safety or efficacy
of the Product. Kitov shall always have the right to representation by counsel of its choice, at its cost, in any of the proceedings
contemplated herein; provided, however, that where, in the reasonable assessment of Kitov’s counsel, a conflict of interest
exists, Coeptis shall bear the costs and expenses of Kitov’s counsel.

 

    12

     

    

 

		12.2.	Indemnity by Kitov. Kitov will defend and indemnify Coeptis, its Affiliates and all of their
officers, directors and employees, from and against any and all claims, damages, costs and expenses actually incurred based upon,
arising out of or relating to (a) Kitov’s negligence or willful misconduct or (b) any material breach of any of Kitov’s
representations or obligations under this Agreement; provided, however, that: (i) Coeptis will have promptly provided Kitov
with written notice thereof and reasonable cooperation, information, and assistance in connection therewith, at Kitov’s cost;
and (ii) where, in the reasonable assessment of Coeptis’s counsel, no conflict of interest exists, Kitov will have control
and authority with respect to the defense, settlement, or compromise thereof; provided that with respect to (ii) above,
in the event that Coeptis undertakes such control and authority, it shall do so at its own cost and expense; and provided further
that no such settlement or compromise will be binding unless approved in writing in advance by the non-controlling Party, and Kitov
will have the sole right to control any claim relating to the safety or efficacy of the Product.

 

		12.3.	Indemnification Limitations. Any right of a person to indemnification under this Agreement
shall not apply to any claims, damages, costs and expenses actually incurred until the aggregate of all such claims, damages, costs
and expenses actually incurred based upon is at least $100,000 (the “Indemnity Basket”), in which event such
indemnity shall apply to all such claims, damages, costs and expenses (including those in the Indemnity Basket).

 

		12.4.	Insurance Coeptis shall obtain and maintain, during the term of this Agreement and thereafter
as contemplated below, comprehensive general liability insurance, including products liability insurance, with reputable and financially
secure insurance carriers in a form and at levels, respectively, that are reasonable and customary in the pharmaceutical industry
for companies of comparable size and activities, but in any event shall be a minimum of US $10,000,000 per occurrence with an annual
aggregate limit of not less than US $10,000,000, with Kitov named as additional insured party/loss payee. The premium of any insurance
will be borne by Coeptis. Such liability insurance shall be maintained on a claims made basis to provide such protection so long
as a third party claim may arise in connection with the Product. Such liability insurance shall be in effect prior to the FCS.

 

		13.	Term and Termination.

 

		13.1.	Term. Unless terminated earlier pursuant to this Section 13, the term of this Agreement
will commence as of the Effective Date and expire on the later of (i) the date on which the last Patent in the Territory expires,
or (ii) the fifteenth anniversary of the Effective Date (the “Initial Term”). The Parties may agree to extend
the Agreement for subsequent two year periods (each such extension a “Renewal Term” and together with the Initial
Term and all preceding Renewal Terms, the “Term”).

 

		13.2.	Termination by either Party. Either Party may terminate this Agreement upon the occurrence
of a breach of any material obligation by the other Party hereunder and the failure of such breaching Party to remedy such breach
within 180 days after having received written notice thereof from the non-breaching Party, any such termination becoming immediately
effective upon the giving of written notice of termination following the expiration of the 180 day period. For the purposes of
clarity and without limiting the generality of this Section 13.2, the Parties hereby acknowledge that failure by Coeptis to meet
the targets set forth in such Marketing Plan for four (4) consecutive calendar quarters shall be considered a material breach of
its obligations for the purposes of the provisions of this Section 13.2.

 

    13

     

    

 

		13.3.	Termination by Kitov/Coeptis.

 

		13.3.1.	Kitov: This Agreement may be terminated by Kitov
immediately upon written notice to Coeptis if (i) FCS has not occurred within **** following the Effective Date; (ii) Coeptis
on more than 2 occasions during a consecutive 12 month period fails to timely pay any amount due to Kitov hereunder within 30
days after receipt of written notice containing a demand for payment therefore; (iii) Coeptis or any of its Affiliates has knowingly
used, copied, marketed, distributed or otherwise transferred any of the Products in any manner constituting a breach of this Agreement
and such breach is not cured within sixty (60) days of written notice to Coeptis, which notice identifies with specificity the
relevant breach, (iv) Coeptis or any of its Affiliates violates, contests or opposes any intellectual property rights associated
with the Product or if Coeptis or any of its Affiliates facilitates such conduct by any third party, (v) upon (A) the filing of
a petition in bankruptcy, insolvency or reorganization against Coeptis, where such petition is not dismissed within 90 days, or
(B) the filing of a petition in bankruptcy, insolvency or reorganization by Coeptis, Coeptis becoming subject to a composition
for creditors, whether by law or agreement, Coeptis going into receivership or Coeptis suspending operations, or (vi) upon failure
by Coeptis to pay a Milestone Payment within 45 days when such Milestone Payment is due.

 

		13.3.2.	Coeptis: This Agreement may be terminated by Coeptis
on each annual anniversary of the Effective Date, provided that Coeptis has provided Kitov with not less than 90 days prior
written notice of such termination.

 

		13.4.	Effect of Termination.

 

		13.4.1.	Upon expiration or termination of this Agreement for any
reason, (i) Coeptis will pay to Kitov all amounts due hereunder as of the date of expiration or termination, (ii) each Party will,
at its own expense, return to the other Party all Confidential Information provided by the other Party as soon as practicable
after the date of such expiration or termination; (iii) Coeptis will cease to promote, market or distribute the Product (except
that Coeptis shall continue to have a limited license hereunder for a period of 180 days from the effective date of the termination
to allow Coeptis to sell any Product remaining in its inventory); and (iv) Coeptis shall transfer to Kitov copies of all regulatory,
marketing and other documentation relating to the Product created during the Term.

 

		13.4.2.	Upon expiration or proper termination of this Agreement
for any reason, the NDA shall be transferred automatically, fully and completely, as of the date of such expiration or termination,
to Kitov, without any additional cost, expense or consideration. Coeptis shall cooperate with Kitov, at Kitov’s cost, and
take all requested steps to affect such transfer, including filing relevant notices to the U.S. Food and Drug Administration.
The parties agree to the following regarding the process for termination:

 

		13.4.2.1.	In the event that Kitov elects to terminate the Agreement,
it must provide written notice of termination to Coeptis (the “Termination Notice”), which notice shall contain
sufficient detail for Coeptis to fully-understand the basis for termination;

 

		13.4.2.2.	If Coeptis disagrees with the basis for termination, Coeptis
shall deliver written notice to Kitov prior to the expiration of the tenth business day following the date on which Coeptis received
the Termination Notice (the “Termination Dispute Notice”). Unless a Termination Dispute Notice is delivered
prior to the end of the ten (10) business day review period, the termination as set forth in the Termination Notice shall be binding
on Coeptis;

 

		13.4.2.3.	If Coeptis delivers a Termination Dispute Notice in a timely
manner, Kitov and Coeptis shall attempt in good faith to resolve the disagreements set forth in the Termination Dispute Notice
for a period of at least thirty (30) days after Kitov’s receipt of the Termination Dispute Notice. If Kitov and Coeptis
are able to resolve the disagreements set forth in the Termination Dispute Notice, they shall reduce such resolution to writing;

 

    14

     

    

 

		13.4.2.4.	If Coeptis and Kitov are not able to resolve the disagreements
set forth in the Termination Dispute Notice within thirty (30) days (or such longer period as they may mutually agree), then,
without prejudice to the provisions of Section 15 below, the parties shall proceed to mediation solely with respect to the dispute
concerning the basis for termination, unless the parties at the time of the dispute agree to a different timeframe. A “notice
of mediation” shall be served, signifying that the negotiation was not successful and to commence the mediation process.
The parties shall agree on a mediator; however, if they cannot agree within ten (10) days then Judicial Arbitration and Mediation
Services, Inc., shall appoint a mediator. The mediation session shall be held within thirty (30) days of the retention of the
mediator, and last for at least one full mediation day. The parties may agree to continue the mediation process beyond one day,
until there is a resolution by the parties, or until the mediator reaches its decision. All reasonable efforts will be made to
complete the mediation within thirty (30) days of the first mediation session. All communications, both written and oral, during
any mediation are confidential and shall be treated as settlement negotiations for purposes of applicable rules of evidence; however,
documents generated in the ordinary course of business prior to the dispute that would otherwise be discoverable, do not become
confidential simply because they are used in the negotiation and/or mediation process. The process shall be confidential based
on terms acceptable to the mediator and/or mediation service provider. The decision of the mediator shall be final and binding
on the parties solely with respect to the dispute concerning the basis for termination. The fees of the mediator shall be split
equally between Kitov and Coeptis: and

 

		13.4.2.5.	In the event that it is determined or otherwise agreed
that Kitov or Copetis has a proper right to terminate the Agreement,, Coeptis then hereby irrevocably appoints Kitov as its attorney-in-fact
to execute and deliver all documents necessary to transfer to Kitov the approved New Drug Application pursuant to, and hereunder,
this Section 13.4.2 of this Agreement. Such appointment is an appointment coupled with an interest and is not revocable by Coeptis.

 

		13.4.3.	Termination of this Agreement for any reason shall be without
prejudice to (i) the obligation of confidentiality; (ii) Kitov’s right to receive all payments that have or may become payable
in respect of any period during which Coeptis was authorized to sell the Product, and all associated rights such as the right
to receive Reports; and (iii) Kitov’s right of inspecting books and account of Coeptis and its Affiliate(s) for any such
period(s), if any, relative to the calculation of Profit Distributions.

 

		13.4.4.	In the event of any termination or upon expiration of this
Agreement, neither Party will have any obligation to the other Party, for compensation or for damages of any kind on account of
the loss by the other Party or any of its employees of present or prospective sales, investments, compensation or goodwill. Each
Party, for itself and on behalf of each of its employees, hereby waives any rights which may be granted to it or them under applicable
laws and regulations or otherwise which are not granted to it or them by this Agreement.

 

		13.4.5.	Survival. Article 6 and Article 13, as well as any
other provisions intended to survive the termination or expiration of this Agreement, shall survive the termination or expiration
of this Agreement. For the avoidance of doubt it is expressly agreed that the confidentiality provisions in Section 6 herein shall
survive in accordance with their terms notwithstanding anything to the contrary in that certain Securities Purchase Agreement
between the Parties and certain other third parties dated on or about the Effective Date.

 

		14.	Notices.

 

All
notices under this Agreement will be in writing and will be given to the Party to which such notice is directed at the following
addresses or addressed to a person or Party at such other address as that Party may have given by written notice in accordance
with this provision:

 

If to
Kitov:    Kitov Pharma Ltd.

One
Azrieli Center

Round
Tower, Floor 19

Tel
Aviv 6701101, Israel

 

Attention:
Isaac Israel

Facsimile:
+972-153-39311321

Email:
i****

 

With
a copy to (which shall not
constitute notice): General Counsel

 Kitov Pharma Ltd.

One
Azrieli Center Round Tower, Floor 19

Tel Aviv 6701101, Israel

 

Attention:
Avraham Ben-Tzivi, Adv.

Facsimile:
+972-153-39311321

Email:
****

 

    15

     

    

 

If
to Coeptis:    105 Bradford Road Suite 420

Wexford,
PA 15090

 

Attention:
Dave Mehalick and Christine Sheehy

Email:
****

     ****

 

With
a copy to (which shall not
constitute notice): Mesiter Seelig & Fein, LLC

125 Park Ave, 7th Floor

New
York, New York 10017

 

Attention:
Denis Dufresne, Esq.

Facsimile: 646-930-4275

Email: ****

 

Notices
given hereunder shall be deemed to have been received as follows: (i) by personal delivery, upon receipt; (ii) by facsimile, one
business day after transmission; (iii) by e-mail, 24 hours after the e-mail was sent, unless the Party sending the e-mail knows
or ought reasonably to suspect that the e-mail was not delivered to the addressee’s domain specified in the e-mail address;
or (iv) by international courier, 5 days after delivery to the courier service by the Party serving notice. If notice is sent by
facsimile or e-mail, a confirming copy of the same shall be sent by mail to the same address.

 

		15.	Law and Dispute Resolution.

 

		15.1.	Governing Law and Jurisdiction. This Agreement is
governed by and shall be construed in accordance with the laws of the State of New York, United States of America, and any disputes
hereunder shall be settled by arbitration in New York City, State of New York, in accordance with the Rules of Conciliation and
Arbitration of the International Chamber of Commerce. The proceedings shall be conducted in the English language and in front
of one arbitrator. Decisions made by the arbitrator shall be made in accordance with the substantive laws of the State of New
York and shall be fully documented. For the purposes of clarity, the procedural laws for court hearings in the State of New York
shall not apply to the arbitration hearings hereunder. Any arbitral award made in accordance with the foregoing shall be enforceable
before, and both Parties hereby consent to the exclusive jurisdiction of, State and federal courts presiding in the County and
State of New York, United States of America, and each of the Parties waive a right to assert a defense of forum non-conveniens.

 

		15.2.	Compliance. Coeptis is responsible for complying
with all laws, standards and regulations in the Territory applicable to the importation, marketing, demonstration, distribution
and sales of the Product, including, without limitation, obtaining any necessary import, insurance, and other certifications,
licenses and permits. Kitov or its designated manufacturer is responsible for complying with all laws, standards and regulations
governing the manufacture and exportation of the Products. Each Party shall be solely responsible, at its sole cost and expense,
for compliance with all laws and regulations governing the conduct of its business in all jurisdictions in which it conducts business.
Each Party will at all times conduct its business in a way that will reflect favorably on the other Party and the Product and
will not knowingly partake in any illegal or questionable business practices.

 

    16

     

    

 

		16.	Miscellaneous.

 

		16.1.	Entire Agreement. This Agreement, which includes all attached exhibits referenced herein,
constitutes the entire agreement between the Parties with respect to the subject matter hereof, and supersedes all prior or contemporaneous
proposals, oral or written and all other communications between the Parties with respect to such subject matter.

 

		16.2.	Force Majeure. Other than with respect to Coeptis’s obligations to make payments to
Kitov as contemplated in this Agreement in a timely manner, neither Kitov nor Coeptis will be liable in damages, or will be subject
to termination of this Agreement by the other Party, for any delay or default in performing any obligation hereunder if that delay
or default is due to any cause beyond the reasonable control and without fault or negligence of that Party; provided that if the
delay results in lack of supply of Product for more than 90 days, Coeptis shall have the right to terminate this Agreement immediately
upon written notice to Kitov. A Party will notify the other of the occurrence or the cause, specifying the nature and particulars
thereof and the expected duration thereof, and within 15 calendar days after the termination of such occurrence or cause, such
Party will give notice to the other Party specifying the date of termination thereof. All obligations of both Parties will return
to being in full force and effect upon the termination of such occurrence or cause (including without limitation any payments which
became due and payable hereunder prior to the termination of such occurrence or cause). For the purposes of clarity, the Parties
hereby acknowledge that the conflict in the State of Israel and its environs shall not be considered a Force Majeure situation
so long as regularly scheduled commercial flights continue to enter and exit Israel; provided, however, that to the extent that
Kitov’s designated manufacturer of the Product is manufacturing the Product in the State of Israel, and any conflict situation
in the State of Israel causes a delay or default in the supply of Product by Kitov due to a cause in connection with such conflict
situation which beyond the reasonable control and without fault or negligence of that Party, such situation will be considered
a Force Majeure situation.

 

		16.3.	Amendment and Waiver. The terms and conditions of this Agreement may not be amended, waived
or modified, except in a writing signed by both Parties. No failure or delay of either Party to exercise any rights or remedies
under this Agreement will operate as a waiver thereof, nor will any single or partial exercise of any rights or remedies preclude
any further or other exercise of the same or any other rights or remedies, nor will any waiver of any rights or remedies with respect
to any circumstances be construed as a waiver thereof with respect to any other circumstances.

 

		16.4.	Invalidity. In the event that any provision of this Agreement is held invalid or unenforceable
in any circumstances by a court of competent jurisdiction, such provision will be replaced by an enforceable provision that most
nearly approximates the intent of the initial provision and the remainder of this Agreement, and the application of such provision
in any other circumstances, will not be affected thereby.

 

		16.5.	Assignment; Subcontracting. Coeptis may not assign, sublicense, or subcontract any of its
rights or obligations pursuant to this Agreement without the prior written consent of Kitov, which consent shall not be unreasonable
conditioned, delayed or withheld, and any attempt to do so without such consent will be void and will entitle Kitov to immediately
terminate this Agreement; provided, however, that Coeptis may (A) assign this Agreement, in whole, or in part, without the
consent of Kitov, to (i) one or more of its Affiliates or (ii) a purchaser or transferee of all or substantially all of Coeptis’
business relating to the Product and (B) enter into co-promotion or similar arrangements, including those arrangements contemplated
by the then in effect Marketing Plan, without the consent of Kitov. Kitov may assign, sublicense or subcontract any of its rights
or obligations hereunder at its discretion.

 

		16.6.	Headings. The headings of sections of this Agreement are for convenience of reference only
and will not affect the meaning or interpretation of this Agreement in any way.

 

    17

     

    

 

		16.7.	Counterparts. This Agreement may be executed in one or more counterparts (including counterparts
executed and delivered by facsimile or by way of e-mail as a pdf or similar attachment, which will be as counterparts executed
and delivered manually), all of which will be considered one and the same agreement and will become effective when one or more
counterparts have been signed by each of the Parties and delivered to the other Party, it being understood that all Parties need
not sign the same counterpart.

 

		16.8.	English Language. This Agreement shall be made in the English language, which language shall
be controlling in all respects. Any and all correspondence between the Parties hereto, including training and technical or other
documents or notices exchanged between the Parties and with third parties relating to this Agreement, shall be in the English language
only.

 

		16.9.	Exhibits. The following exhibits form an integral part of this Agreement:

 

	Exhibit A:	Product
	Exhibit B:	CMC Plan
	Exhibit C:	Kitov Patents and Marks
	Exhibit D:	Pre-Launch Marketing Plan

 

		17.	Definitions and Interpretation.

 

		17.1.	References to Defined Terms. Definitions of the following terms used herein may be found
at the sections referenced below:

 

	 	“Agreement”	Preamble
	 	 	 
	 	“Annual Marketing Plans”	3.1.1
	 	 	 
	 	“Confidential Information”	6.1
	 	 	 
	 	“Corrupt Practices Laws”	9.1
	 	 	 
	 	“Customer”	1.1
	 	 	 
	 	“Disclosing Party”	6.1

 

    18

     

    

 

	 	“Effective Date”	Preamble
	 	 	 
	 	“FCS”	2.3.1.3
	 	 	 
	 	“Initial Term”	13.1
	 	 	 
	 	“Invoicing Entity”	2.3.6
	 	 	 
	 	“Joint Steering Committee” or “JSC”	5
	 	 	 
	 	“Kitov”	Preamble
	 	 	 
	 	“Coeptis”	Preamble
	 	 	 
	 	“Marketing Plan”	3.1.1
	 	 	 
	 	“Marks”	4.3
	 	 	 
	 	“Milestone Payment”	2.3.1
	 	 	 
	 	“Net Sales”	2.3.6
	 	 	 
	 	“Net Profits”	2.3.4
	 	 	 
	 	“Non-Compete”	1.5
	 	 	 
	 	“Pre-Launch Marketing Plan”	3.1.1
	 	 	 
	 	“Product”	Preamble
	 	 	 
	 	“Receiving Party”	6.1
	 	 	 
	 	“Renewal Term”	13.1
	 	 	 
	 	“Report”	3.4
	 	 	 
	 	“Representatives”	5
	 	 	 
	 	“Term”	13.1
	 	 	 
	 	“Territory”	1.3

 

		17.2.	In addition, “Party” may refer to either
Kitov or Coeptis individually, and “Parties” may refer to both Kitov and Coeptis together. Furthermore, “Affiliate”
as used in this Agreement, shall mean, with respect to a Party, any person, organization or entity controlling, controlled by
or under common control with, such Party. For purposes of this definition only, “control” of another person, organization
or entity shall mean the possession, directly or indirectly, of the power to direct or cause the direction of the activities,
management or policies of such person, organization or entity, whether through the ownership of voting securities, by contract
or otherwise. Without limiting the foregoing, control shall be presumed to exist when a person, organization or entity (i) owns
or directly controls 50% or more of the outstanding voting stock or other ownership interest of the other organization or entity,
or (ii) possesses, directly or indirectly, the power to elect or appoint 50% or more of the members of the governing body of the
organization or other entity.

 

		17.2.	Interpretation. The Parties have participated jointly
in the negotiation and drafting of this Agreement, and were both represented by professional counsel in, the preparation of this
Agreement. In the event an ambiguity or question of intent or interpretation arises, in any judicial proceeding or otherwise,
the terms of this Agreement shall be construed as having been drafted jointly by the Parties, and no presumption or burden of
proof shall arise favoring or disfavoring any Party by virtue of the authorship of any provisions of this Agreement Interpretation.
The Parties have participated jointly in the negotiation and drafting of this Agreement, and were both represented by professional
counsel in, the preparation of this Agreement. In the event an ambiguity or question of intent or interpretation arises, in any
judicial proceeding or otherwise, the terms of this Agreement shall be construed as having been drafted jointly by the Parties,
and no presumption or burden of proof shall arise favoring or disfavoring any Party by virtue of the authorship of any provisions
of this Agreement.

 

[Remainder
of page intentionally left blank. Signature page follows.]

 

    19

     

    

 

[Signature
page to Agreement]

 

IN
WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed on the day and year first above written.

 

	Kitov Pharma Ltd.	 	Coeptis Pharmaceuticals, Inc.
	 	 	 	 	 
	By:	                                        	 	By:	                                        
	Name:	 	 	Name:	 
	Title:	 	 	Title:	 

 

    20

     

    

 

EXHIBIT
A

PRODUCT
DESCRIPTION

 

NDA210045
- Consensi (Amlodipine Besylate; Celecoxib)

 

The
fixed dose combination of celecoxib and amlodipine prescription product, referred to as ConsensiTM, in all oral dosage forms
approved for marketing by the FDA, for use in the Territory.

 

    21

     

    

 

EXHIBIT B:

CMC
PLAN for ConsensiTM

 

	Item Description	 	Target Date
	
        Validation
        Batches

        **** Batches
        of each of the following strengths (**** batched total):

         

        CELECOXIB/AMLODIPINE
        200/2.5MG **** TABLETS

         

        CELECOXIB/AMLODIPINE
        200/5MG

        **** TABLETS

         

        CELECOXIB/AMLODIPINE
        200/10 MG

        **** TABLETS

         

        TOTAL: ****
        TABLETS
	 	 
	 	 	 
	Scale Up (between **** and **** batches)	 	 
	 	 	 
	Stability of validation batches	 	 
	 	 	 
	Packaging: Bulk	 	 
	 	 	 
	Elemental Impurities Assessment	 	to be concluded prior to ****
	 	 	 
	Dissolution Method and Acceptance Criteria Development	 	Final Report Submission due ****

 

Completion
of CMC Plan means (i) the submission of the validation report to the FDA and (ii) delivery of the manufactured Validation Batches
tablets to Coeptis (ExWorks).

 

    22

     

    

 

EXHIBIT
C

KITOV
PATENTS AND MARKS

 

1)
Trademarks:

 

The US trademark
ConsensiTM, which was granted by FDA.

 

Notice of allowance
for the trademark ConsensiTM was received (in January 2018) from the USPTO.

 

	W&C IP
        Docket Number:	 	Trademark:	 	Status:	 	Application
        Number:	 	Filing Date:	 	Publication
        Number:	 	Publication
        Date:	 	Allow
        Dal
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	10990010MA	 	CONSENSI	 	Published	 	87/295,108	 	10-Jan-2017	 	GAZETTE	 	28-Nov-2017	 	23-Jan-

 

2)
Patents:

 

	AMELIORATING DRUG-INDUCED ELEVATIONS IN BLOOD PRESSURE VIA ADJUNCTIVE USE OF AT LEAST ON
	 
	W&C IP Docket Number:	 	Country:	 	CaseType	 	Status	 	Application:	 	Filing Date:
	 	 	 	 	 	 	 	 	 	 	 
	10990004AA	 	US	 	ORD	 	ISSUED	 	13/026,741	 	14-Feb-2011
	 	 	 	 	 	 	 	 	 	 	 
	10990004BA	 	US	 	DIV	 	ISSUED	 	14/936,739	 	10-Nov-2015
	 	 	 	 	 	 	 	 	 	 	 
	CELECOXIB AND AMLODIPINE FORMULATION AND METHOD OF MAKING THE SAME
	 
	W&C IP Docket Number:	 	Country:	 	CaseType	 	Status	 	Application:	 	Filing Date:
	 	 	 	 	 	 	 	 	 	 	 
	10990007AA	 	US	 	PCT	 	Pending	 	16/008,538	 	14-Jun-2018
	 	 	 	 	 	 	 	 	 	 	 
	10990007TA	 	WO (PCT Filing)	 	ORD	 	Pending	 	PCT/IL2018/050728	 	04-Jul-2018

 

    23

     

    

 

EXHIBIT
D

PRE-LAUNCH
MARKETING PLAN

 

	Activity	 	Purpose/Description	 	$ Estimate2	 	Responsible	 	Target Deadline
	 	 	 	 	 	 	 	 	 
	Patient
Registry - US Safety	 	****	 	$****	 	Coeptis	 	 
	Marketing Plan	 	****	 	$****	 	Coeptis	 	 
	Shipping	 	****	 	$****	 	Coeptis	 	 
	Sales Force	 	****	 	$****	 	Coeptis	 	 

 

2
Certain of these estimated costs will be incurred post-launch during the early stages of the commercialization of the Product.

 

 

 

 

24

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00293-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00293-of-00352.parquet"}]]